[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 64 of about 64
1. Tsiambas E, Rigopoulos DN, Kravvaritis C, Lazaris AC, Kavantzas N, Niotis A, Niotis TH, Tsounis D, Karameris A, Patsouris E: Chromogenic in situ hybridization analysis of EGFR gene copies in colon adenocarcinoma based on intra-operative imprints and tissue microarrays. J Gastrointestin Liver Dis; 2009 Sep;18(3):293-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromogenic in situ hybridization analysis of EGFR gene copies in colon adenocarcinoma based on intra-operative imprints and tissue microarrays.
  • BACKGROUND: Although Epidermal Growth Factor Receptor (EGFR) over expression is a frequent event in colon adenocarcinoma (CA), identification of EGFR gene deregulation mechanisms--combined to k-ras mutations--remains the basic criterion for rational application of anti-EGFR targeted therapeutic strategies.
  • Chromogenic in situ hybridization (CISH) was performed using EGFR gene and chromosome 7 centromeric probes in the tissue microarray and also in the corresponding intra-operative imprints.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Gene Dosage. Genes, erbB-1. In Situ Hybridization / methods. Tissue Array Analysis / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795022.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  •  go-up   go-down


2. Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A, Schmidt WE, Tannapfel A: Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut; 2007 Aug;56(8):1047-53
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma.
  • BACKGROUND: The suppressors of cytokine signalling (SOCS) are inhibitors of cytokine signalling; methylation of SOCS-3 has been implicated in the tumorigenesis of liver as well as head and neck cancer.
  • AIMS: This study was performed to elucidate the role of SOCS-1 and SOCS-3 in Barrett's adenocarcinoma and its precursor lesions.
  • CONCLUSIONS: These data indicate that promoter methylation and subsequent transcript downregulation of SOCS-3 transcripts and, to a much lesser extent, SOCS-1 are involved in the multistep carcinogenesis of Barrett's adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Suppressor of Cytokine Signaling Proteins / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Carcinoma, Squamous Cell / genetics. Cell Line, Tumor. CpG Islands / genetics. DNA, Neoplasm / genetics. Humans. Methylation. Neoplasm Proteins / genetics. Promoter Regions, Genetic / genetics. Transcription, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):1003-9 [15386345.001]
  • [Cites] Dig Dis. 2004;22(2):126-33 [15383753.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i21-6 [15711004.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i6-12 [15711008.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6699-708 [16007169.001]
  • [Cites] J Hepatol. 2005 Nov;43(5):757-63 [16083990.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1314-21 [16288283.001]
  • [Cites] Biochem Pharmacol. 2006 Mar 14;71(6):713-21 [16426581.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1117-28 [16618406.001]
  • [Cites] J Clin Invest. 2006 Jun;116(6):1571-81 [16710471.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6546-52 [16818626.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):179-93 [16831601.001]
  • [Cites] Gut. 2006 Sep;55(9):1263-9 [16682432.001]
  • [Cites] Shock. 2006 Sep;26(3):226-34 [16912647.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5059-63 [10537273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] Nat Genet. 2001 May;28(1):29-35 [11326271.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):460-5 [11331873.001]
  • [Cites] Cancer Lett. 2002 Dec 1;186(1):59-65 [12183076.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1807-8; discussion 1807-8 [12229925.001]
  • [Cites] Lancet. 2002 Nov 16;360(9345):1587-9 [12443613.001]
  • [Cites] J Hum Genet. 2003;48(2):65-9 [12601549.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2784-8 [12456503.001]
  • [Cites] APMIS. 2002 Dec;110(12):833-44 [12645661.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4134-42 [12821948.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):338-43 [12865927.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4757-9 [12879021.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1101-7 [12937151.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14133-8 [14617776.001]
  • [Cites] Trends Immunol. 2003 Dec;24(12):659-66 [14644140.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52021-31 [14522994.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):554-8 [14724583.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • (PMID = 17376806.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / SOCS1 protein, human; 0 / SOCS3 protein, human; 0 / Suppressor of Cytokine Signaling Proteins
  • [Other-IDs] NLM/ PMC1955493
  •  go-up   go-down


3. Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S, Cestari R: TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology; 2010 Jul;57(1):81-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
  • AIMS: Topoisomerase IIalpha (TOPOIIalpha) and HER-2/neu are chromosome 17q genes coamplified in various cancers; no data exist for Barrett's oesophagus (BO) and BO adenocarcinoma (ADC).
  • METHODS AND RESULTS: Forty-four patients [18 BO, 13 BO with dysplasia (five low-grade dysplasia, eight high-grade dysplasia) and 13 ADC in BO] were evaluated by immunohistochemistry and fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antigens, Neoplasm / genetics. Barrett Esophagus / genetics. Barrett Esophagus / pathology. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Genes, erbB-2
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Chromosomes, Human, Pair 17 / genetics. Diagnosis, Differential. Female. Gene Amplification. Gene Expression. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2006;53(5):393-401 [17013533.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2893-8 [17363613.001]
  • [Cites] Dig Liver Dis. 2007 Apr;39(4):305-11 [17307036.001]
  • [Cites] Mod Pathol. 2007 May;20(5):584-91 [17396141.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):768-72 [16882699.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5115-23 [17785566.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):403-9 [18261624.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6440-8 [18927283.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Dec;54(4):347-53 [19047975.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3826-33 [19292734.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Anal Cell Pathol. 2000;20(1):25-32 [11007435.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8 [11121461.001]
  • [Cites] J Clin Pathol. 2000 Dec;53(12):890-2 [11265171.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3857-62 [12473600.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):179-86 [14499010.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):288-97 [14978790.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):233-7 [14990588.001]
  • [Cites] Neoplasma. 2004;51(3):193-7 [15254672.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):63-70 [1980607.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):195-211 [7795268.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):761-8 [9284825.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1180-8 [9343325.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60 [9747866.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):28-35 [15762277.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • (PMID = 20557373.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2916224
  •  go-up   go-down


Advertisement
4. Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, Welsch T, Schirrmacher P, Klöppel G, Altevogt P, Schäfer H, Sebens Müerköster S: Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol Rep; 2010 Oct;24(4):909-15
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma.
  • Recently, we identified L1CAM expression in pancreatic ductal adenocarcinoma (PDAC) cells accounting for chemoresistance and increased cell migration.
  • L1CAM expression was determined by immunohistochemistry in tissues of 123 patients including tissues of 110 primary PDACs, 15 lymph node metastases and 14 liver metastases.
  • The immunohistochemical analyses revealed L1CAM expression in 92.7% of primary PDACs, 80% of lymph node metastases and 100% of liver metastases.
  • [MeSH-major] Carcinoma in Situ / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Neural Cell Adhesion Molecule L1 / biosynthesis. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811670.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


5. Kumashiro Y, Yao T, Aishima S, Hirahashi M, Nishiyama K, Yamada T, Takayanagi R, Tsuneyoshi M: Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol; 2007 Jun;38(6):857-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype.
  • Hepatoid adenocarcinoma is an extrahepatic tumor characterized by morphological similarities to hepatocellular carcinoma.
  • The lesions contain a tubular adenocarcinoma that seems to develop "hepatoid" features, but the relation between the tubular adenocarcinomatous and the hepatoid components remains unclear.
  • We compared the cellular phenotypes of 23 cases of hepatoid adenocarcinoma of the stomach having tubular adenocarcinomatous components with 69 cases of non-hepatoid adenocarcinoma of the stomach.
  • Afterward, we examined the expression of CDX2 and p53 in the tubular adenocarcinomatous and hepatoid components of hepatoid adenocarcinoma.
  • Both components of hepatoid adenocarcinoma were classified into 4 phenotypic categories according to the immunohistochemical results for CD10, MUC2, MUC5AC, and MUC6.
  • In contrast, no gastric phenotype (MUC5AC+, MUC6+, MUC2-, CD10-) was observed in any of the hepatoid adenocarcinoma components.
  • These findings suggest that hepatoid adenocarcinoma arises from an adenocarcinoma with an intestinal phenotype and that its hepatoid component is in some way related to reduced CDX2 expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Homeodomain Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Aged. Albumins / metabolism. Disease Progression. Humans. Immunohistochemistry. In Situ Hybridization. Intestinal Mucosa / pathology. Liver Neoplasms / pathology. Middle Aged. Mucin-2. Mucin-6. Mucins / metabolism. Neprilysin / metabolism. Phenotype. RNA, Messenger / analysis. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320150.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / MUC6 protein, human; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 0 / alpha-Fetoproteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


6. Shinji S, Naito Z, Ishiwata T, Tanaka N, Furukawa K, Suzuki H, Seya T, Kan H, Tsuruta H, Matsumoto S, Matsuda A, Teranishi N, Ohaki Y, Tajiri T: Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis. Int J Oncol; 2006 Aug;29(2):357-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis.
  • Poorly differentiated (PD) adenocarcinoma often retains the capacity for neuroendocrine (NE) cell differ-entiation; however, it is difficult to distinguish the NE cell differentiation by routine hematoxylin and eosin staining.
  • It is important to detect the presence of NE cell differentiation in advanced colorectal carcinomas because these carcinomas have been shown to produce distant metastasis at the time of diagnosis and to have a particularly poor prognosis.
  • In this study, the characteristics of PD adenocarcinoma with NE cell differentiation and its biological metastatic mechanisms were investigated.
  • Forty-eight of 2204 colorectal cancer patients, diagnosed as having PD adenocarcinoma (2.2%) were enrolled in this study.
  • The clinicopathological factors for PD adenocarcinoma with NE cell differentiation were compared with those for PD adenocarcinoma without NE cell differentiation.
  • Microvessel density (MVD) was assessed using immunostained slides with anti-CD34 antibody and vascular endothelial growth factor (VEGF) expression in PD adenocarcinoma with NE cell differentiation was confirmed by in situ hybridization.
  • By immunohistochemical staining for chromogranin A and synaptophysin, NE cell differentiation was detected in eight of 48 patients (16.7%) with PD adenocarcinoma.
  • The frequency of liver metastasis at the time of diagnosis was significantly higher in patients having PD adenocarcinoma with NE cell differentiation (p=0.03).
  • Moreover, MVD and VEGF expression level tended to be higher in patients having PD adenocarcinoma with NE cell differentiation (p=0.13 and 0.068, respectively).
  • NE cell differentiation in PD adenocarcinoma may produce liver metastasis through microvessel formation in the tumor induced by VEGF.
  • In PD colorectal adenocarcinoma, immunohistochemical analysis of NE markers is important for establishing the presence of NE cell differentiation and further study is necessary to evaluate the effectiveness of anti-angiogenic drugs to PD adenocarcinoma with NE cell differentiation.
  • [MeSH-major] Adenocarcinoma / metabolism. Antibodies, Monoclonal / chemistry. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / metabolism. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD34 / biosynthesis. Cell Differentiation. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820877.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD34; 0 / monoclonal antibody D2-40
  •  go-up   go-down


7. Guerra C, Schuhmacher AJ, Cañamero M, Grippo PJ, Verdaguer L, Pérez-Gallego L, Dubus P, Sandgren EP, Barbacid M: Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell; 2007 Mar;11(3):291-302
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.
  • Pancreatic ductal adenocarcinoma (PDA), one of the deadliest human cancers, often involves somatic activation of K-Ras oncogenes.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Genes, ras. Pancreatic Neoplasms / pathology. Pancreatitis, Chronic / pathology
  • [MeSH-minor] Animals. Cell Lineage. Cell Transformation, Neoplastic. Ceruletide. Doxycycline / pharmacology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Mice. Mice, Mutant Strains. Mutation. Neoplasm Invasiveness. Pancreas / pathology. Signal Transduction


8. Mózsik G, Rumi G, Dömötör A, Figler M, Gasztonyi B, Papp E, Pár A, Pár G, Belágyi J, Matus Z, Melegh B: Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary. World J Gastroenterol; 2005 Dec 28;11(48):7646-50
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary.
  • AIM: To analyze the serum levels of retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers.
  • METHODS: The changes in serum levels of retinoids (vitamin A, alpha- and beta-carotene, alpha- and beta-cryptoxanthin, zeaxanthin, lutein) and Leiden mutation were measured by high liquid performance chromatography (HPLC) and polymerase chain reaction (PCR) in 107 patients (70 males/37 females) with esophageal (0/8), gastric (16/5), liver (8/7), pancreatic (6/4), and colorectal (30/21 including 9 patients suffering from in situ colon cancer) cancer.
  • CONCLUSION: Retinoids (as environmental factors) are decreased significantly with increased prevalence of Leiden mutation (as a genetic factor) in patients before the clinical manifestation of histologically different (planocellular and hepatocellular carcinoma, and adenocarcinoma) GI cancer.
  • [MeSH-major] Colorectal Neoplasms / blood. Esophageal Neoplasms / blood. Factor V / genetics. Liver Neoplasms / blood. Pancreatic Neoplasms / blood. Point Mutation. Retinoids / blood. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437692.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Retinoids; 0 / Xanthophylls; 0 / Zeaxanthins; 0 / factor V Leiden; 01YAE03M7J / beta Carotene; 11103-57-4 / Vitamin A; 9001-24-5 / Factor V
  • [Other-IDs] NLM/ PMC4727222
  •  go-up   go-down


9. Kadikoylu G, Yavasoglu I, Barutca S, Meydan N, Bolaman Z: Chronic myeloid leukemia following the treatment of rectal adenocarcinoma. Med Oncol; 2008;25(4):467-70
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
  • He had no symptoms and physical findings 3 years after treatment for rectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Neoplasms, Second Primary / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Fusion Proteins, bcr-abl / genetics. Humans. In Situ Hybridization, Fluorescence. Leucovorin / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Organoplatinum Compounds / administration & dosage. Philadelphia Chromosome. Quinazolines / administration & dosage. Reverse Transcriptase Polymerase Chain Reaction. Thiophenes / administration & dosage

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 1994 Apr;24(2):111-5 [8158858.001]
  • [Cites] Leuk Lymphoma. 1997 Oct;27(3-4):365-7 [9402335.001]
  • [Cites] Ann Oncol. 2006 Jun;17 (6):1025-6 [16293675.001]
  • [Cites] Leuk Lymphoma. 2007 May;48(5):1032-3 [17487750.001]
  • [Cites] Leuk Res. 1999 Oct;23(10):961-4 [10573143.001]
  • [Cites] Clin Lab Haematol. 2003 Oct;25(5):329-31 [12974726.001]
  • [Cites] N Engl J Med. 1999 Feb 4;340(5):351-7 [9929525.001]
  • [Cites] Leuk Lymphoma. 1998 Mar;29(1-2):17-26 [9638972.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):119-37 [11355927.001]
  • [Cites] Pol Tyg Lek. 1996 May;51(19-22):289-90 [9289713.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):306-12 [1738180.001]
  • [Cites] Drug Saf. 2006;29(3):209-30 [16524321.001]
  • [Cites] Ann Hematol. 2000 Jul;79(7):396-401 [10965789.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1571-4 [9305614.001]
  • [Cites] Haematologia (Budap). 2002;32(4):501-3 [12803125.001]
  • [Cites] Ann Hematol. 1999 Aug;78(8):341-54 [10460347.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):342-7 [17499346.001]
  • [Cites] Br J Clin Pract. 1990 Feb;44(2):76-8 [2383470.001]
  • [Cites] Haematologica. 1993 Jan-Feb;78(1):56-7 [8387943.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):447-8 [16494624.001]
  • [Cites] Oncologist. 2006 Mar;11(3):261-2 [16549810.001]
  • [Cites] Acta Oncol. 2008;47(3):464-6 [17851873.001]
  • [Cites] Br J Cancer. 1991 May;63(5):782-8 [2039704.001]
  • (PMID = 18373227.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 04ZR38536J / oxaliplatin; 0H43101T0J / irinotecan; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.2 / Fusion Proteins, bcr-abl; FCB9EGG971 / raltitrexed; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Vullierme MP, Giraud-Cohen M, Hammel P, Sauvanet A, Couvelard A, O'Toole D, Levy P, Ruszniewski P, Vilgrain V: Malignant intraductal papillary mucinous neoplasm of the pancreas: in situ versus invasive carcinoma surgical resectability. Radiology; 2007 Nov;245(2):483-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant intraductal papillary mucinous neoplasm of the pancreas: in situ versus invasive carcinoma surgical resectability.
  • PURPOSE: To retrospectively evaluate computed tomographic (CT) findings in patients with in situ and invasive malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and to evaluate the accuracy for surgical resectability, with surgery and pathologic analysis as the reference standards.
  • CT findings were retrospectively evaluated to determine if a pancreatic malignant IPMN tumor was present; to make this determination, CT criteria were used to differentiate in situ from invasive tumors and signs of unresectability (liver metastasis, vascular CT pattern of encasement, or regional lymph node metastasis).
  • RESULTS: CT revealed a mural nodule in the pancreatic duct wall in 14 patients with in situ carcinoma and one patient with invasive carcinoma (P < .003).
  • CT revealed an infiltrative pancreatic mass in 17 patients with invasive carcinoma and two patients with in situ carcinoma (P < .02).
  • Of the mural nodules, 93% were seen in patients with in situ carcinoma, whereas 90% of infiltrative pancreatic masses were observed in patients with invasive carcinomas.
  • CONCLUSION: CT is helpful in the differentiation of in situ and invasive IPMN.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / surgery. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / radiography. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / radiography. Adenocarcinoma, Papillary / surgery. Adult. Aged. Female. Humans. Male. Preoperative Care / methods. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848678.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Hajek RA, King DW, Hernández-Valero MA, Kaufman RH, Liang JC, Chilton JA, Edwards CL, Wharton JT, Jones LA: Detection of chromosomal aberrations by fluorescence in situ hybridization in cervicovaginal biopsies from women exposed to diethylstilbestrol in utero. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):318-24
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal aberrations by fluorescence in situ hybridization in cervicovaginal biopsies from women exposed to diethylstilbestrol in utero.
  • Epidemiologic studies have associated estrogens with human neoplasms such as those in the endometrium, cervix, vagina, breast, and liver.
  • In order to determine whether this effect was associated with chromosomal changes in humans, the frequencies of trisomy of chromosomes 1, 7, 11, and 17 were evaluated by the fluorescence in situ hybridization (FISH) technique in cervicovaginal tissue from 19 DES-exposed and 19 control women.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / pathology. Adult. Biopsy, Needle. Case-Control Studies. Female. Humans. In Situ Hybridization, Fluorescence. Incidence. Probability. Reference Values. Risk Assessment. Sensitivity and Specificity. Tissue Culture Techniques. Uterine Cervical Neoplasms / chemically induced. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / chemically induced. Vaginal Neoplasms / epidemiology. Vaginal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445652.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 16672; United States / NIMHD NIH HHS / MD / P60 MD 00503; United States / NCI NIH HHS / CA / R01 CA 44591; United States / NCI NIH HHS / CA / R01 CA 69375A-05S4; United States / NICHD NIH HHS / HD / T32 HD 07324; United States / ODCDC CDC HHS / CC / U48 CCU 619515-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


12. Kokura S, Yoshida N, Ishikawa T, Higashihara H, Sakamoto N, Takagi T, Uchiyama K, Naito Y, Mazda O, Okanoue T, Yoshikawa T: Interleukin-10 plasmid DNA inhibits subcutaneous tumor growth of Colon 26 adenocarcinoma in mice. Cancer Lett; 2005 Feb 10;218(2):171-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-10 plasmid DNA inhibits subcutaneous tumor growth of Colon 26 adenocarcinoma in mice.
  • In vitro study: Colon 26 murine colon adenocarcinoma cells were either treated or untreated with IL-10 for 60 min.
  • In vivo study: to induce a high level of IL-10 in plasma, we transferred the naked plasmid vectors encoding the mouse IL-10 gene into the liver via the intravenous route.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy. Genetic Therapy. Interleukin-10 / genetics. Skin Neoplasms / prevention & control
  • [MeSH-minor] Animals. Apoptosis / drug effects. DNA / metabolism. In Situ Nick-End Labeling. Inhibitor of Apoptosis Proteins. Male. Mice. Mice, Inbred BALB C. Microtubule-Associated Proteins / analysis. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. Plasmids. Proto-Oncogene Proteins c-bcl-2 / analysis. Repressor Proteins. Tumor Necrosis Factor-alpha / pharmacology. bcl-X Protein / analysis

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670894.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Birc5 protein, mouse; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Repressor Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / bcl-X Protein; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA
  •  go-up   go-down


13. Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, Maeda N, Yanagihara K, Yokozaki H: High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch; 2007 Mar;450(3):303-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
  • Phosphatase of regenerating liver (PRL)-3, encoding a 22-kD low molecular weight tyrosine phosphatase, has been reported to be associated with metastasis of colorectal carcinoma.
  • Levels of PRL-3 expression in 94 human gastric adenocarcinomas and 54 matched lymph node metastases were detected by in situ hybridization and compared with clinicopathological characteristics including prognosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. In Situ Hybridization / methods. Neoplasm Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Nodes. Male. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Neoplasm Staging. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Ther. 2002 Feb-Mar;93(2-3):307-17 [12191622.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8 [11355880.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1517-22 [16873432.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Int Rev Cytol. 2001;204:49-95 [11243597.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] Hybrid Hybridomics. 2004 Feb;23(1):23-7 [15000845.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(8):2444-8 [3162770.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12 ):3824-31 [12473596.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21444-52 [10747914.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37 [16875667.001]
  • [Cites] Ann Surg. 1978 Dec;188(6):711-5 [736648.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Br J Surg. 1970 Dec;57(12):877-83 [5487028.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):179-83 [16472776.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3153-61 [16540666.001]
  • [Cites] J Histochem Cytochem. 1993 Apr;41(4):499-506 [8095509.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] FEBS Lett. 2004 May 7;565(1-3):181-7 [15135076.001]
  • [Cites] Cancer Lett. 2003 Dec 30;202(2):201-11 [14643450.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii31-6 [12810455.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):347-54 [16832410.001]
  • [Cites] Mol Cell Biol. 1991 Jan;11(1):381-90 [1986233.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • (PMID = 17235563.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


14. Takahashi Y, Kawate S, Watanabe M, Fukushima J, Mori S, Fukusato T: Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver. Pathol Int; 2007 Jul;57(7):437-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver.
  • However, there have been few reports on the amplification of both these genes in primary and metastatic liver carcinomas.
  • In the present study, c-myc and cyclin D1 gene amplification was examined in 76 primary and metastatic liver carcinomas using formalin-fixed paraffin-embedded tissue sections and a differential polymerase chain reaction procedure. c-myc and cyclin D1 gene amplification was detected in 15 (33%) and two (4%) of 46 hepatocellular carcinomas (HCC), one (10%) and 0 (0%) of 10 intrahepatic cholangiocarcinomas (ICC), one (33%) and 0 (0%) of three combined hepatocellular and cholangiocarcinomas (HCC + ICC), and nine (56%) and three (19%) of 16 metastatic lesions to the liver from colorectal adenocarcinoma (MCA), respectively.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclins / genetics. Gene Amplification. Liver Neoplasms / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / secondary. Cholangiocarcinoma / genetics. Cholangiocarcinoma / secondary. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Cyclin D. Humans. In Situ Hybridization, Fluorescence. Neoplasms, Multiple Primary. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587243.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Cyclins; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


15. Cardoso J, Nievas S, Pereira M, Schwint A, Trivillin V, Pozzi E, Heber E, Monti Hughes A, Sanchez P, Bumaschny E, Itoiz M, Liberman S: Boron biodistribution study in colorectal liver metastases patients in Argentina. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S76-9
Hazardous Substances Data Bank. BORON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron biodistribution study in colorectal liver metastases patients in Argentina.
  • Ex-situ BNCT for multifocal unresectable liver metastases employing whole or partial autograft techniques requires knowledge of boron concentrations in healthy liver and metastases following perfusion and immersion in Wisconsin solution (W), the procedure employed for organ preservation during ex-situ irradiation.
  • Measurements of boron concentration in blood, liver and metastases following an intravenous infusion of BPA-F in five colorectal liver metastases patients scheduled for surgery were performed.
  • The data showed a dose-dependent BPA uptake in liver, a boron concentration ratio liver/blood close to 1 and a wide spread in the metastases/liver concentration ratios in the range 0.8-3.6, partially attributable to histological variations between samples.
  • Based on the boron concentrations and dose considerations (liver < or =15 Gy-Eq and tumor> or =40 Gy-Eq) at the RA-3 thermal neutron facility (mean flux of about (6+/-1) x 10(9) n cm(-2)s(-1)), ex-situ treatment of liver metastases at RA-3 would be feasible.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Boron / pharmacokinetics. Colorectal Neoplasms / metabolism. Liver Neoplasms / metabolism. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Argentina. Boron Compounds / administration & dosage. Boron Compounds / pharmacokinetics. Boron Compounds / therapeutic use. Boron Neutron Capture Therapy. Female. Humans. In Vitro Techniques. Infusions, Intravenous. Isotopes / blood. Isotopes / pharmacokinetics. Liver / metabolism. Liver Transplantation. Male. Middle Aged. Phenylalanine / administration & dosage. Phenylalanine / analogs & derivatives. Phenylalanine / pharmacokinetics. Phenylalanine / therapeutic use. Radiation-Sensitizing Agents / administration & dosage. Radiation-Sensitizing Agents / pharmacokinetics. Radiation-Sensitizing Agents / therapeutic use. Tissue Distribution. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375931.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boron Compounds; 0 / Isotopes; 0 / Radiation-Sensitizing Agents; 47E5O17Y3R / Phenylalanine; N9E3X5056Q / Boron; UID84303EL / 4-boronophenylalanine
  •  go-up   go-down


16. Sayagués JM, Abad Mdel M, Melchor HB, Gutiérrez ML, González-González M, Jensen E, Bengoechea O, Fonseca E, Orfao A, Muñoz-Bellvis L: Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis. J Pathol; 2010 Jul;221(3):308-19
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis.
  • We analyse the frequency of abnormalities for 47 chromosome regions using the interphase fluorescence in situ hybridization technique in a group of 48 tumours, including 24 primary colorectal tumours and 24 paired liver metastases.
  • Interestingly, the liver metastases typically contained tumour cell clones similar to those found in the primary tumours, suggesting the absence of selective selection of specific tumour clones.
  • Owing to the high frequency of numerical abnormalities of the entire chromosome 7 and loss and/or gain/amplification of specific regions of chromosome 8, eg del(8p22) and/or gains/amplification of 8q24 in primary colorectal tumours with associated metastases, it is suggested that their assessment at diagnosis could be of great clinical utility for the identification of colorectal cancer patients at higher risk of developing liver metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / genetics. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Aged, 80 and over. Chromosome Aberrations. DNA, Neoplasm / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neoplasm Staging. Neoplastic Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 20527024.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


17. Iwaya K, Oikawa K, Semba S, Tsuchiya B, Mukai Y, Otsubo T, Nagao T, Izumi M, Kuroda M, Domoto H, Mukai K: Correlation between liver metastasis of the colocalization of actin-related protein 2 and 3 complex and WAVE2 in colorectal carcinoma. Cancer Sci; 2007 Jul;98(7):992-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between liver metastasis of the colocalization of actin-related protein 2 and 3 complex and WAVE2 in colorectal carcinoma.
  • In order to determine whether the same mechanism correlates with liver metastasis from colorectal cancer, paired mirror sections of 154 cancer specimens (29 cases with liver metastasis and 125 cases without liver metastasis in which T factor, gender, primary tumor site, and age at operation were matched) were examined immunohistochemically for the localization of Arp2 and WAVE2.
  • Univariate analysis showed that the colocalization was significantly predictive of liver metastasis (risk ratio [RR] 8.760.
  • High mRNA levels of Arp2, that in situ hybridization revealed to be expressed by the cancer cells, were significantly associated with liver metastasis.
  • These results indicate that the colocalization of Arp2 and WAVE2 is an independent risk factor for liver metastasis of colorectal carcinoma.
  • [MeSH-major] Actin-Related Protein 2 / physiology. Actin-Related Protein 3 / physiology. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Wiskott-Aldrich Syndrome Protein Family / physiology
  • [MeSH-minor] Actins / physiology. Adenocarcinoma / blood supply. Adenocarcinoma / pathology. DNA Primers. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Neoplasm Invasiveness. Polymerase Chain Reaction. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459058.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actin-Related Protein 2; 0 / Actin-Related Protein 3; 0 / Actins; 0 / DNA Primers; 0 / RNA, Messenger; 0 / WASF2 protein, human; 0 / Wiskott-Aldrich Syndrome Protein Family
  •  go-up   go-down


18. Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D, Rahbari N, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Beckhove P, Weitz J: Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol; 2008 Aug;15(8):2310-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer.
  • BACKGROUND: Tumor-infiltrating T lymphocytes (TIL) play an important role in primary colorectal cancer, but their activity in liver metastases has not yet been investigated.
  • The aim of this study was to examine whether tumor-selective infiltration, activation, and cytotoxic activity of TIL can be demonstrated in situ in colorectal liver metastases.
  • METHODS: TIL were obtained from liver metastases and corresponding normal liver tissue of 16 patients with colorectal liver metastases.
  • Characterization of TIL in situ was performed by multicolor flowcytometric analysis.
  • RESULTS: TIL in colorectal liver metastases responding against tumor antigens were present in most patients.
  • Although the proportions of CD3(+) T cells were comparable in liver metastasis and normal liver tissue, metastases contained significantly enhanced proportions of CD4(+) cells (49% vs. 22%, P < .001).
  • Among all CD4(+) T helper cells, the proportion of activated (CD4(+)CD25(+)) effector cells was significantly increased in liver metastases (15.0% vs. 7.8%, P = .003).
  • Importantly, the presence of activated T helper cells correlated with the frequencies of cytotoxic T lymphocytes that exerted cytotoxic activity in situ (P = .02).
  • CONCLUSION: CD4(+) and CD8(+) TIL are selectively activated in liver metastases, and cytotoxic T lymphocytes exert tumor-selective cytotoxic activity in situ in the presence of activated T helper cells, suggesting the requirement of in-situ-activated T helper cells for efficient cytotoxic T lymphocytes effector function.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Lymphocytes, Tumor-Infiltrating. T-Lymphocyte Subsets

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2009 Apr;16(4):1084. Rahbari, Nuh [added]
  • (PMID = 18521684.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


19. Precup CG, Gonganau-Nitu D, Scurtu RR, Dindelegan G, Biro A, Soritau O, Crişan C, Serban O, Pufu G, Ciuce C: Assessement by laser Doppler of the peripheral tumour perfusion after radiofrequency ablation for colorectal liver mestasis--experimental study. Chirurgia (Bucur); 2010 Jan-Feb;105(1):71-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessement by laser Doppler of the peripheral tumour perfusion after radiofrequency ablation for colorectal liver mestasis--experimental study.
  • Non-resecable liver metastases might be destroyed in situ by radiofrequency although the local recurrence is still very important.
  • Colorectal adenocarcinoma (CC531s) was used for liver tumour inoculationin on 15 Wag/Rij rats.
  • [MeSH-major] Adenocarcinoma / blood supply. Catheter Ablation. Colorectal Neoplasms / blood supply. Laser-Doppler Flowmetry. Liver Neoplasms / blood supply
  • [MeSH-minor] Animals. Disease Models, Animal. Hepatectomy / methods. Male. Microcirculation / radiation effects. Neoplasm Regression, Spontaneous. Neoplasm Staging. Rats. Rats, Wistar. Risk Assessment. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405683.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  •  go-up   go-down


20. Borgonovo G, Razzetta F, Assalino M, Varaldo E, Puglisi M, Ceppa P: Rectal hepatoid carcinoma with liver metastases in a patient affected by ulcerative colitis. Hepatobiliary Pancreat Dis Int; 2008 Oct;7(5):539-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal hepatoid carcinoma with liver metastases in a patient affected by ulcerative colitis.
  • We present a case of rectal hepatoid adenocarcinoma with metachronous liver metastases.
  • METHODS: Four months after total procto-colectomy for a rectal adenocarcinoma (Astler-Coller C2), a 42-year-old man with ulcerative colitis showed hypoechoic masses in the hepatic parenchyma by abdominal ultrasonography.
  • Fine-needle biopsy revealed that liver masses were positive for hepatocellular carcinoma.
  • RESULTS: Immunohistochemistry and albumin mRNA in situ hybridization suggested that the nodules were metastases of a HT.
  • He died from liver failure 19 months after initial diagnosis.
  • The preoperative diagnosis of this tumor requires a high degree of suspicion, the availability of a panel of immunohistochemical markers, and a certain amount of luck.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Hepatocellular / secondary. Colitis, Ulcerative / complications. Liver Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Chemoembolization, Therapeutic. Diagnostic Errors. Fatal Outcome. Hepatectomy. Humans. Immunohistochemistry. Male. Neoplasm Staging. Proctocolectomy, Restorative. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18842504.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Sato K, Ueda Y, Yokoi M, Hayashi K, Kosaka T, Katsuda S: Reactive lymphoid hyperplasia of the liver in a patient with multiple carcinomas: a case report and brief review. J Clin Pathol; 2006 Sep;59(9):990-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactive lymphoid hyperplasia of the liver in a patient with multiple carcinomas: a case report and brief review.
  • A rare case of reactive lymphoid hyperplasia (RLH) of the liver in a 75-year-old woman admitted to hospital for surgical treatment of gastric, caecal and colon carcinomas is described here.
  • Two nodular lesions in the left and right lobes of the liver were clinically diagnosed as metastatic tumours by computed tomography of the abdomen.
  • A demarcating grey-white mass of size 1.4 cm was observed in a partially resected liver specimen.
  • No evidence of monoclonality was observed by immunohistochemistry for B and T cell markers, in situ hybridisation for kappa and lambda light chains, and polymerase chain reaction analysis of immunoglobulin heavy chains or T cell receptor beta and gamma gene rearrangements.
  • RLH, formerly known as pseudolymphoma, has been reported of the liver in only 14 cases and is considered to be a differential diagnosis of small nodular lesions of the liver.
  • [MeSH-major] Liver Diseases / pathology. Pseudolymphoma / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Aged. Diagnosis, Differential. Female. Gastrointestinal Neoplasms / complications. Humans. Liver Neoplasms / pathology. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):721-31 [11395549.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jan;105(1):46-9 [6893912.001]
  • [Cites] Zentralbl Allg Pathol. 1987;133(6):565-8 [3328445.001]
  • [Cites] J Clin Gastroenterol. 1993 Apr;16(3):240-4 [8505499.001]
  • [Cites] Intern Med. 1994 Jan;33(1):18-22 [7514058.001]
  • [Cites] Pathol Int. 1994 Sep;44(9):704-11 [7804433.001]
  • [Cites] Scand J Rheumatol. 2001;30(2):117-9 [11324789.001]
  • [Cites] J Hepatol. 1997 Jan;26(1):209-14 [9148014.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Feb;14(2):163-7 [10029298.001]
  • [Cites] Am J Surg Pathol. 1999 Mar;23(3):302-8 [10078921.001]
  • [Cites] Cancer. 1963 Jul;16:928-55 [14043765.001]
  • [Cites] J Pathol. 2000 Nov;192(3):277-9 [11054708.001]
  • [Cites] Arch Pathol Lab Med. 2001 Apr;125(4):577-8 [11260645.001]
  • [Cites] Pathol Int. 1996 Oct;46(10):782-6 [8916149.001]
  • (PMID = 16935975.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 15
  • [Other-IDs] NLM/ PMC1860472
  •  go-up   go-down


22. Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E: Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol; 2006 Oct;45(4):568-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efforts should be made to detect early neoplastic changes that can be radically treated by liver transplantation.
  • RESULTS: Among patients with cytological low-grade (n=9; 15%) or high-grade dysplasia/adenocarcinoma (n=13; 21%), 8 (36%) proved to have cholangiocarcinoma and 7 (32%) to have high-grade dysplasia (i.e. cholangiocarcinoma in situ) in bile ducts from explanted livers.
  • The sensitivity, specificity, positive- and negative predictive values, and accuracy of brush cytology in diagnosis of biliary malignancy were 100%, 84%, 68%, 100%, and 88% for the combination of low-grade and high-grade dysplasia/adenocarcinoma and 73%, 95%, 85%, 91%, and 90% for high-grade dysplasia/adenocarcinoma only.
  • CONCLUSIONS: Brush cytology from bile duct strictures in PSC patients can detect cholangiocarcinoma in situ.
  • Patients with cytological low-grade and high-grade dysplasia/adenocarcinoma are currently referred for liver transplantation in our hospital.
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Biomarkers, Tumor. Carcinoma in Situ / pathology. Cholangiopancreatography, Endoscopic Retrograde. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Hepatol. 2006 Oct;45(4):476-9 [16901574.001]
  • (PMID = 16879890.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Ricci F, Kern SE, Hruban RH, Iacobuzio-Donahue CA: Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. Cancer Biol Ther; 2005 Mar;4(3):302-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using nonradioactive in situ hybridization, we evaluated the gene expression patterns of three genes previously shown to be robust markers of the juxtatumoral stroma within eight infiltrating ductal adenocarcinoma of the pancreas (ApoC1, ApoD and MMP11), and compared these patterns to those associated with seven infiltrating colloid and tubular carcinomas arising in association with intraductal papillary mucinous neoplasms (IPMNs), a histologically distinct form of primary carcinoma of the pancreas, two surgically resected samples of chronic pancreatitis and two surgically resected pancreatic cancer liver metastases.
  • Robust juxtatumoral stromal expression was noted for all three markers within all eight conventional infiltrating ductal adenocarcinoma tissues, but not in samples of chronic pancreatitis.
  • This observation was further supported by two infiltrating carcinomas arising in an IPMN that showed both tubular and colloid growth patterns within the same neoplasm indicating the host stromal response observed may relate to infiltrative growth pattern rather than the biology of the primary tumor type.
  • Moreover, these robust patterns within conventional infiltrating ductal adenocarcinomas were not retained within matched metastases to the liver, indicating the importance of the tumor microenvironment in the host stromal response.
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / secondary. Apolipoprotein C-I. Apolipoproteins / analysis. Apolipoproteins / genetics. Apolipoproteins C / analysis. Apolipoproteins C / genetics. Apolipoproteins D. Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / secondary. Cell Communication / genetics. Gene Expression. Glycoproteins / analysis. Glycoproteins / genetics. Humans. In Situ Hybridization. Liver Neoplasms / chemistry. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Matrix Metalloproteinase 11. Membrane Transport Proteins / analysis. Membrane Transport Proteins / genetics. Metalloendopeptidases / analysis. Metalloendopeptidases / genetics. RNA, Messenger / analysis. RNA, Messenger / metabolism. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876873.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA1066110; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APOD protein, human; 0 / Apolipoprotein C-I; 0 / Apolipoproteins; 0 / Apolipoproteins C; 0 / Apolipoproteins D; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


24. Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Danø K, Nielsen BS: MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res; 2006 May;4(5):293-302
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To test whether MMP-9 is also induced in tumor edge macrophages in metastases from colorectal adenocarcinomas, we have compared the expression pattern of MMP-9 in primary colorectal adenocarcinomas (n = 15) with that in liver metastases (n = 15) and local lymph node metastases (n = 7) from the same patients by in situ hybridization and immunohistochemistry.
  • In contrast, only 3 of the 15 liver metastases had MMP-9 mRNA and immunoreactivity at the periphery, and this expression was confined to small foci of macrophages located either among lymphocytes or in a dense desmoplastic stroma.
  • Expression of MMP-9 mRNA and immunoreactivity was in all liver metastases seen in macrophages located in the lumen of malignant glandular structures and in central necrotic tissue.
  • We conclude that MMP-9 is not up-regulated in tumor edge macrophages in liver metastases like in their primary tumor and local lymph node metastases, suggesting that disseminating colorectal cancer cells can adopt alternative proteolytic mechanisms for invasion depending on the local microenvironment.
  • [MeSH-major] Adenocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Matrix Metalloproteinase 9 / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies / chemistry. Female. Humans. Immunoenzyme Techniques / methods. In Situ Hybridization / methods. Liver Neoplasms / enzymology. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687484.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / RNA, Messenger; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


25. Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S: Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem; 2006 Jan;54(1):63-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated levels of SAA in the serum of cancer patients were suggested to be of liver origin rather than a tumor cell product.
  • Nonradioactive in situ hybridization applied on paraffin tissue sections from 26 colon cancer patients revealed barely detected SAA mRNA expression in normal looking colonic epithelium.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenomatous Polyps / metabolism. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. In Situ Hybridization. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymph Nodes / metabolism. Lymphatic Metastasis. Male. Middle Aged. Omentum / metabolism. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116035.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Serum Amyloid A Protein
  •  go-up   go-down


26. Liang ZY, Wang WZ, Gao J, Wu SF, Zeng X, Liu TH: [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas]. Zhonghua Bing Li Xue Za Zhi; 2007 Feb;36(2):102-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expressions of TOP2A and HER2/neu proteins were detected by using immunohistochemistry, while gene amplifications of TOP2A and HER2/neu were assessed by using multi-color fluorescence in situ hybridization (FISH).
  • By FISH, 9/10 TOP2A amplified adenocarcinomas showed TOP2A and HER2/neu gene coamplification, while one case with HER2/neu gene amplification adenocarcinoma showed no TOP2A amplification.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / metabolism. Carcinoma, Pancreatic Ductal / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Genes, erbB-2. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493384.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


27. Reuss R, Aberle S, Klingel K, Sauter M, Greschniok A, Franke FE, Padberg W, Blin N: The expression of the carboxyl ester lipase gene in pancreas and pancreatic adenocarcinomas. Int J Oncol; 2006 Sep;29(3):649-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-five tumor samples, 24 samples of normal pancreatic tissue and control tissues from other organs were examined by radioactive in situ hybridization (ISH) to localize CEL mRNA.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / genetics. Carcinoma, Acinar Cell / enzymology. Carcinoma, Acinar Cell / genetics. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Pancreatic Ductal / genetics. Humans. In Situ Hybridization. Liver Neoplasms / enzymology. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Pancreatitis / enzymology. Pancreatitis / genetics. RNA Probes. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865281.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA Probes; 0 / RNA, Messenger; EC 3.1.1.3 / CEL protein, human; EC 3.1.1.3 / Lipase
  •  go-up   go-down


28. Abdullah M, Schultz H, Kähler D, Branscheid D, Dalhoff K, Zabel P, Vollmer E, Goldmann T: Expression of the acute phase protein haptoglobin in human lung cancer and tumor-free lung tissues. Pathol Res Pract; 2009;205(9):639-47
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-seven specimens were subjected to mRNA-in situ hybridization.
  • In situ hybridization verified the results of immunohistochemistry.
  • The results were further verified by RT-PCR and Western blot compared to liver tissues, which both showed comparable amounts of haptoglobin mRNA and protein in NSCLC and in liver, while tumor-free lung tissues showed lower expression.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Western. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Reverse Transcriptase Polymerase Chain Reaction. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / pathology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501987.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Haptoglobins
  •  go-up   go-down


29. Sanada Y, Yoshida K, Ohara M, Tsutani Y: Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res; 2007;13(2):105-13
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma in Situ / enzymology. Carcinoma, Hepatocellular / enzymology. Gallbladder Neoplasms / enzymology. Liver Neoplasms / enzymology. Orotate Phosphoribosyltransferase / metabolism. Pancreatic Neoplasms / enzymology
  • [MeSH-minor] Aged. Female. Gallbladder / enzymology. Gallbladder / pathology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Liver / enzymology. Liver / pathology. Male. Middle Aged. Pancreas / enzymology. Pancreas / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreatology. 2006;6(5):429-39 [16847380.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):987-92 [16142362.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Nov;32(12):1929-34 [16282729.001]
  • [Cites] Pancreas. 2004 Apr;28(3):257-62 [15084967.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):607-15 [16880781.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):245-9 [16012756.001]
  • [Cites] Eur J Cancer. 2003 May;39(7):975-80 [12706367.001]
  • [Cites] Pancreas. 2006 Mar;32(2):164-70 [16552336.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):45-50 [16788943.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):723-31 [14770427.001]
  • [Cites] Pancreas. 2005 Apr;30(3):223-6 [15782098.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):230-6 [1309358.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1223-30 [16211289.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):492-8 [16734727.001]
  • [Cites] Cancer. 2006 May 1;106(9):1990-7 [16565970.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):39-62 [15757804.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):621-8 [15105650.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):345-51 [15993511.001]
  • (PMID = 17607371.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.4.2.10 / Orotate Phosphoribosyltransferase
  •  go-up   go-down


30. De Caro G, Pagano N, Malesci A, Hervoso C, Danese S, Romeo F, Delconte G, Repici A: Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer: a case report. Dig Liver Dis; 2009 Jul;41(7):e32-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 72-year-old woman underwent gastric endoscopic mucosal resection with a cap-fitted endoscope for an adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / surgery. Gastroscopy / adverse effects. Neoplasm Recurrence, Local / surgery. Stomach Diseases / etiology. Stomach Neoplasms / surgery. Surgical Instruments

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620913.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


31. Fellig Y, Ariel I, Ohana P, Schachter P, Sinelnikov I, Birman T, Ayesh S, Schneider T, de Groot N, Czerniak A, Hochberg A: H19 expression in hepatic metastases from a range of human carcinomas. J Clin Pathol; 2005 Oct;58(10):1064-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Non-radioactive in situ hybridisation for H19 RNA was performed on paraffin wax embedded sections of liver biopsies or partial hepatectomy specimens, taken from 80 patients with hepatic metastases derived from carcinomas from several medical centres in Israel.
  • The medical files were searched for demographic data and survival times before and after diagnosis of hepatic metastases.
  • Further studies are needed to determine whether H19 expression has prognostic value in metastatic liver disease using larger numbers of specific subtypes of primary carcinomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Liver Neoplasms / genetics. Liver Neoplasms / secondary. RNA, Untranslated / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adult. Aged. Colorectal Neoplasms / genetics. Female. Gene Expression. Humans. In Situ Hybridization / methods. Male. Middle Aged. Prognosis. RNA, Long Noncoding. RNA, Neoplasm / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2004 Feb 1;13(3):353-61 [14681296.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):587-606 [15062663.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):659-71 [15062667.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):521-5 [15228427.001]
  • [Cites] Mol Cancer. 2002 Jul 11;1:2 [12234381.001]
  • [Cites] Nature. 1993 Oct 21;365(6448):764-7 [7692308.001]
  • [Cites] Gynecol Oncol. 1994 May;53(2):212-9 [8188082.001]
  • [Cites] J Natl Cancer Inst. 1994 Jul 20;86(14):1070-5 [8021956.001]
  • [Cites] Nat Genet. 1994 Jul;7(3):440-7 [7920666.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2159-63 [7534414.001]
  • [Cites] Cancer Res. 1996 Feb 1;56(3):480-2 [8564957.001]
  • [Cites] Biol Cell. 1995;85(2-3):117-24 [8785513.001]
  • [Cites] Oncogene. 1997 Jan 9;14(1):95-107 [9010236.001]
  • [Cites] Oncogene. 1997 Jul 10;15(2):169-77 [9244352.001]
  • [Cites] Mol Pathol. 1998 Feb;51(1):21-5 [9624415.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1597-607 [9811352.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):18-25 [9921969.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):7-11 [10428315.001]
  • [Cites] J Gene Med. 2005 Mar;7(3):366-74 [15521051.001]
  • [Cites] Mol Pathol. 2000 Dec;53(6):320-3 [11193051.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):645-50 [11920631.001]
  • [Cites] Exp Cell Res. 2002 May 1;275(2):215-29 [11969291.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4545-8 [12183402.001]
  • [Cites] Mol Carcinog. 2002 Oct;35(2):63-74 [12325036.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1885-95 [12419837.001]
  • [Cites] Clin Liver Dis. 2002 Nov;6(4):1033-43, x [12516205.001]
  • [Cites] Am J Surg. 2003 Feb;185(2):158-64 [12559448.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):179-87 [12569573.001]
  • [Cites] Lancet. 2003 Feb 1;361(9355):358-9 [12573366.001]
  • [Cites] Hum Mol Genet. 2003 Mar 1;12(5):535-49 [12588801.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):272-89 [12594662.001]
  • [Cites] Mol Ther. 2003 Apr;7(4):535-41 [12727117.001]
  • [Cites] J Surg Res. 2004 Mar;117(1):144-53 [15013725.001]
  • (PMID = 16189152.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / H19 long non-coding RNA; 0 / RNA, Long Noncoding; 0 / RNA, Neoplasm; 0 / RNA, Untranslated
  • [Other-IDs] NLM/ PMC1770739
  •  go-up   go-down


32. Sánchez-Pérez B, Santoyo-Santoyo J, Suárez-Muñoz MA, Fernández-Aguilar JL, Aranda-Narváez JM, González-Sánchez A, de la Fuente-Perucho A: [Hepatic cystic endometriosis with malignant transformation]. Cir Esp; 2006 May;79(5):310-2
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnostic method of choice is abdominal CT, which should always be used in the differential diagnosis of cystic liver masses.
  • We report a case of in situ adenocarcinoma arising in a hepatic endometrioma, which was treated with right hepatectomy.
  • [MeSH-major] Adenocarcinoma / pathology. Endometriosis / pathology. Liver Diseases / pathology. Liver Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753122.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 11
  •  go-up   go-down


33. Semino-Mora C, Liu H, McAvoy T, Nieroda C, Studeman K, Sardi A, Dubois A: Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol; 2008 May;15(5):1414-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Pseudomyxoma peritonei (PMP) is characterized by peritoneal tumors arising from a perforated appendiceal adenoma or adenocarcinoma, but associated entry of enteric bacteria in the peritoneum has not been considered as a cofactor.
  • METHODS: In situ hybridization was performed on resection specimens from five control subjects with noninflamed, nonperforated, non-neoplastic appendix and 16 patients with PMP [six with disseminated peritoneal adenomucinosis (DPAM) and 10 with peritoneal mucinous carcinomatosis (PMCA)].

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Immun. 1993 May;61(5):1799-809 [8478069.001]
  • [Cites] Lancet. 1992 Nov 14;340(8829):1194-5 [1359263.001]
  • [Cites] J Histochem Cytochem. 1995 Feb;43(2):115-23 [7529784.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Clin Infect Dis. 1996 Jul;23(1):101-6 [8816137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):967-72 [9023366.001]
  • [Cites] Mutat Res. 1997 Jun 13;391(1-2):79-86 [9219551.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1128-33 [9781653.001]
  • [Cites] Toxicon. 1999 May;37(5):815-23 [10219991.001]
  • [Cites] J Immunol. 1999 May 15;162(10):6233-7 [10229869.001]
  • [Cites] Ann Chir. 2005 Feb;130(2):63-9 [15737316.001]
  • [Cites] Lab Invest. 2005 May;85(5):702-15 [15765119.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Helicobacter. 2006 Feb;11(1):2-9 [16423084.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):551-9 [16699309.001]
  • [Cites] Cancer Lett. 2006 Nov 28;244(1):86-90 [16427185.001]
  • [Cites] Inflamm Bowel Dis. 2006 Nov;12(11):1068-83 [17075348.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e110 [17121461.001]
  • [Cites] Gastroenterology. 2007 Feb;132(2):551-61 [17258726.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1009-23 [17383424.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5 [17481516.001]
  • [Cites] Biochim Biophys Acta. 1998 Apr 28;1406(3):251-9 [9630659.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):458-63 [11260116.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):164-71 [11266521.001]
  • [Cites] J Radiol. 2001 Apr;82(4):463-8 [11353901.001]
  • [Cites] Surg Today. 2001;31(7):646-50 [11495161.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2253-7 [12057927.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):551-64 [12163380.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):958-72 [12218214.001]
  • [Cites] Mol Pharmacol. 2002 Nov;62(5):1112-8 [12391274.001]
  • [Cites] J Obstet Gynaecol. 2002 Mar;22(2):223 [12521714.001]
  • [Cites] J Infect Dis. 2003 Apr 15;187(8):1165-77 [12695995.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • [Cites] Ann Intern Med. 2004 Apr 20;140(8):W33 [15096365.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17 [15194558.001]
  • [Cites] Acta Chir Scand. 1973;139(4):392-400 [4718184.001]
  • [Cites] J Histochem Cytochem. 1987 Sep;35(9):983-96 [3302022.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1636-40 [2208015.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • (PMID = 18299935.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082312-08; United States / NCI NIH HHS / CA / R01 CA082312; United States / NCI NIH HHS / CA / CA82312; United States / NCI NIH HHS / CA / R01 CA082312-08
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Probes; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins; 0 / RNA Probes
  • [Other-IDs] NLM/ NIHMS72052; NLM/ PMC2570966
  •  go-up   go-down


34. Boissan M, De Wever O, Lizarraga F, Wendum D, Poincloux R, Chignard N, Desbois-Mouthon C, Dufour S, Nawrocki-Raby B, Birembaut P, Bracke M, Chavrier P, Gespach C, Lacombe ML: Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res; 2010 Oct 1;70(19):7710-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conversely, NM23-H1 was dispensable for cancer cell proliferation in vitro and liver regeneration in NM23-M1 null mice, instead inducing cellular resistance to chemotherapeutic drugs in vitro.
  • Analysis of NM23-H1 expression in clinical specimens revealed high expression in premalignant lesions (liver cirrhosis and colon adenoma) and the central body of primary liver or colon tumors, but downregulation at the invasive front of tumors.
  • Our findings reveal that NM23-H1 is critical for control of cell-cell adhesion and cell migration at early stages of the invasive program in epithelial cancers, orchestrating a barrier against conversion of in situ carcinoma into invasive malignancy.
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Movement / genetics. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Cytoskeleton / metabolism. Cytoskeleton / pathology. Gene Silencing. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Matrix Metalloproteinase 14 / metabolism. Neoplasm Invasiveness. Wnt Proteins / metabolism


35. Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, García Mde L, Medina RA, Carrasco M, Barberis S, Castro T, Martínez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Pérez F, Nualart F: Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol; 2006 Jun;207(3):614-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GLUT6 was principally detected in testis germinal cells and GLUT9 was localized in kidney, liver, heart, and adrenal.
  • GLUT2 was detected in 31% of the samples, being mainly expressed in breast, colon, and liver carcinoma.
  • GLUT5 was detected in 27% of breast and colon adenocarcinoma, liver carcinoma, lymphomas, and testis seminoma samples.
  • In situ RT-PCR and ultrastructural immunohistochemistry confirmed GLUT5 expression in breast cancer.
  • [MeSH-minor] Animals. Biopsy. Gene Expression Regulation, Neoplastic. Health. Humans. Immunohistochemistry. In Situ Hybridization. Mice. Microscopy, Immunoelectron. Organ Specificity. Rats. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16523487.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative
  •  go-up   go-down


36. Li J, Zhou J, Chen G, Wang H, Wang S, Xing H, Gao Q, Lu Y, He Y, Ma D: Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model. Cancer Gene Ther; 2006 Mar;13(3):266-72
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer is one of the most threatening malignant tumors in females due to the frequent occurrence of metastasis that precedes diagnosis.
  • Liver metastasis and animal survival time were measured after transfer of a recombinant adeno-associated viral vector expressing nm23H1 (AAV-nm23H1) into the aforementioned model.
  • Intraperitoneal injection of AAV-nm23H1 into this orthotopic implantation model of ovarian cancer resulted in (1) expression of the exogenous gene in more than 95% of tumor cells in situ in nude mice;.
  • (2) a 60% reduction in the number of animals developing liver metastases; and (3) a 35-day prolongation of median survival time compared with the untreated host group.
  • [MeSH-major] Dependovirus / genetics. Disease Models, Animal. Genetic Therapy. Liver Neoplasms / prevention & control. Nucleoside-Diphosphate Kinase / genetics. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Animals. Cell Line, Tumor. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. NM23 Nucleoside Diphosphate Kinases. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179930.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  •  go-up   go-down


37. Arndt S, Bosserhoff AK: Reduced expression of TANGO in colon and hepatocellular carcinomas. Oncol Rep; 2007 Oct;18(4):885-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results were confirmed in situ by immunohistochemistry on paraffin-embedded sections of colon and hepatocellular tumors.
  • [MeSH-major] Aryl Hydrocarbon Receptor Nuclear Translocator / metabolism. Carcinoma, Hepatocellular / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Liver Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Line, Tumor. Down-Regulation. Humans. Immunoenzyme Techniques. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786351.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ARNT protein, human; 0 / RNA, Messenger; 138391-32-9 / Aryl Hydrocarbon Receptor Nuclear Translocator
  •  go-up   go-down


38. Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, Levy MJ, Halling KC: Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn; 2010 Nov;12(6):780-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study was to determine whether KRAS mutations could be identified in residual pancreatobiliary stricture brushings and to compare the performance characteristics of KRAS mutation analysis to cytology and fluorescence in situ hybridization (FISH) for the detection of carcinoma.
  • Residual brushing cytology cell pellets were retrieved from 132 patients with subsequent clinicopathologic follow-up of cholangiocarcinoma (n = 41), pancreatic adenocarcinoma (n = 35), gallbladder cancer (n = 2), and nonmalignant strictures (n = 54).
  • KRAS mutations and polysomic (ie, positive) FISH results were identified in 24 (69%) and 22 (63%) pancreatic adenocarcinoma specimens, respectively, with a combined sensitivity of 86% (30/35).
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Cholangiopancreatography, Endoscopic Retrograde. Cytodiagnosis / methods. DNA Mutational Analysis / methods. In Situ Hybridization, Fluorescence / methods. Pancreatic Neoplasms / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Jun 25;93(3):229-35 [11391612.001]
  • [Cites] Gut. 2001 Mar;48(3):403-8 [11171833.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):214-9 [15017605.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):139-54 [15192787.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1675-81 [15330900.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):629-35 [10100716.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):412-20 [15467712.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] J Clin Pathol. 2005 Dec;58(12):1315-20 [16311354.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1064-72 [17030177.001]
  • [Cites] Diagn Cytopathol. 2007 Apr;35(4):218-24 [17351944.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):272-9 [17638662.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3714-20 [17659731.001]
  • [Cites] J Clin Gastroenterol. 2007 Nov-Dec;41(10):906-10 [18090159.001]
  • [Cites] Liver Int. 2008 Jan;28(1):12-27 [18031477.001]
  • [Cites] World J Gastroenterol. 2008 Feb 21;14(7):1097-101 [18286693.001]
  • [Cites] Hepatology. 2008 Jul;48(1):308-21 [18536057.001]
  • [Cites] Cancer Biol Ther. 2008 Mar;7(3):353-360 [18075308.001]
  • [Cites] Oncol Res. 2008;17(4):151-7 [18773859.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Nov;6(11):1270-8 [18995218.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2180-6 [19232347.001]
  • [Cites] Adv Anat Pathol. 2009 Jul;16(4):196-203 [19546608.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):519-27 [19636327.001]
  • [Cites] Gastroenterology. 2009 Sep;137(3):1072-82, 1082.e1-6 [19501586.001]
  • [Cites] Arch Pathol Lab Med. 2009 Oct;133(10):1600-6 [19792050.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):543-52 [19815694.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):583-9 [19815696.001]
  • [Cites] Pancreas. 2009 Nov;38(8):890-5 [19752775.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):387-92 [10705391.001]
  • [Cites] Diagn Cytopathol. 2002 May;26(5):273-7 [11992366.001]
  • (PMID = 20864634.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2963905
  •  go-up   go-down


39. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM: Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res; 2008 Aug 15;68(16):6779-88
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The vast majority of cases arise in the context of chronic liver injury due to hepatitis B virus or hepatitis C virus infection.
  • Fluorescence in situ hybridization on an independent validation set of 210 tumors found 6p21 high-level gains in 14 tumors, as well as 2 tumors with 6p21 amplifications.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2004 Dec;36(12):1306-11 [15565109.001]
  • [Cites] Hepatology. 1996 Mar;23(3):455-64 [8617424.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2667-76 [15829978.001]
  • [Cites] BMC Bioinformatics. 2005;6:107 [15850491.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2050-7 [16000397.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):599-608 [16314847.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):99-106 [16491069.001]
  • [Cites] World J Gastroenterol. 2006 Feb 21;12(7):1140-3 [16534861.001]
  • [Cites] Nat Med. 2006 Apr;12(4):410-6 [16532004.001]
  • [Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]
  • [Cites] FEBS Lett. 2006 Jun 26;580(15):3571-81 [16750200.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):99-111 [16904609.001]
  • [Cites] Genome Biol. 2006;7 Suppl 1:S12.1-14 [16925834.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):674-87 [16929323.001]
  • [Cites] Oncogene. 2006 Sep 7;25(40):5581-90 [16785998.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1262-70 [17030195.001]
  • [Cites] Genome Res. 2006 Dec;16(12):1575-84 [17122084.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1758-67 [17087938.001]
  • [Cites] Hepatology. 2007 Jan;45(1):42-52 [17187432.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):901-10 [17283120.001]
  • [Cites] J Virol. 2007 Apr;81(7):3391-401 [17267482.001]
  • [Cites] Hepatology. 2007 Apr;45(4):938-47 [17393520.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2713-22 [17717605.001]
  • [Cites] Gastroenterology. 2007 Nov;133(5):1475-86 [17983802.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1451-61 [18316609.001]
  • [Cites] Gut. 2008 Apr;57(4):516-24 [17895355.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1312-27 [18821591.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):431-40 [10930378.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1763-73 [11375957.001]
  • [Cites] J Hepatol. 2001 May;34(5):683-9 [11434614.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):1929-39 [12058060.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8293-301 [12447692.001]
  • [Cites] Science. 2003 Feb 7;299(5608):890-3 [12574630.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1242-9 [14578863.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1374-86 [15131798.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6058-64 [15342387.001]
  • [Cites] Hepatology. 2004 Sep;40(3):667-76 [15349906.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1354-60 [15376182.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3107-10 [8205525.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):935-41 [15756261.001]
  • (PMID = 18701503.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK076986-01; United States / NIDDK NIH HHS / DK / DK076986; United States / NIDDK NIH HHS / DK / R01 DK076986; United States / NCI NIH HHS / CA / R01 CA109038; United States / NCI NIH HHS / CA / CA109038; United States / NIDDK NIH HHS / DK / R01 DK037340; United States / NIDDK NIH HHS / DK / DK076986-01; United States / NIDDK NIH HHS / DK / DK037340
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS55968; NLM/ PMC2587454
  •  go-up   go-down


40. Leung SC, Lo PC, Ng DK, Liu WK, Fung KP, Fong WP: Photodynamic activity of BAM-SiPc, an unsymmetrical bisamino silicon(IV) phthalocyanine, in tumour-bearing nude mice. Br J Pharmacol; 2008 May;154(1):4-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumour volume in the hepatocarcinoma HepG2- and the colorectal adenocarcinoma HT29-bearing nude mice was measured after photodynamic therapy.
  • Finally, the metabolism of BAM-SiPc in the 'normal' WRL68 liver cells and the hepatocarcinoma HepG2 cells was compared.
  • BAM-SiPc could be metabolized by WRL68 liver cells but not by the hepatocarcinoma HepG2 cells.
  • [MeSH-minor] Animals. Cell Line, Tumor. HT29 Cells. Humans. In Situ Nick-End Labeling. In Vitro Techniques. Liver / pathology. Mice. Mice, Nude. Neoplasm Transplantation. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2006 Apr;154(4):747-50 [16536822.001]
  • [Cites] Curr Pharm Des. 2005;11(9):1151-65 [15853663.001]
  • [Cites] J Photochem Photobiol B. 2006 Oct 2;85(1):56-64 [16765603.001]
  • [Cites] Oncologist. 2006 Oct;11(9):1034-44 [17030646.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2006;16(4):279-305 [17206921.001]
  • [Cites] Curr Med Chem. 2007;14(15):1673-87 [17584072.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):413-8 [16481739.001]
  • [Cites] Photochem Photobiol. 2002 Feb;75(2):140-8 [11883602.001]
  • [Cites] Photochem Photobiol Sci. 2002 Sep;1(9):709-14 [12665310.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1806-13 [12702566.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):380-7 [12724736.001]
  • [Cites] Lasers Med Sci. 2003;18(3):134-8 [14505196.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):662-72 [15126603.001]
  • [Cites] Lancet Oncol. 2004 Aug;5(8):497-508 [15288239.001]
  • [Cites] Chem Commun (Camb). 2004 Oct 7;(19):2236-7 [15467889.001]
  • [Cites] Cancer Res. 1979 Jan;39(1):146-51 [761185.001]
  • [Cites] Lasers Surg Med. 1990;10(5):485-8 [2146455.001]
  • [Cites] J Med Chem. 1994 Feb 4;37(3):415-20 [8308868.001]
  • [Cites] J Photochem Photobiol B. 1995 Oct;30(2-3):201-8 [8558370.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1886-90 [8980386.001]
  • [Cites] J Photochem Photobiol B. 1997 Sep;40(2):163-7 [9345784.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1533-41 [10408394.001]
  • [Cites] J Natl Cancer Inst. 1961 Jan;26:1-11 [13762612.001]
  • [CommentIn] Br J Pharmacol. 2008 May;154(1):1-3 [18362894.001]
  • (PMID = 18332853.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAM-SiPc; 0 / Indoles; 0 / Organosilicon Compounds; 0 / Photosensitizing Agents
  • [Other-IDs] NLM/ PMC2438983
  •  go-up   go-down


41. Jaiswal K, Lopez-Guzman C, Souza RF, Spechler SJ, Sarosi GA Jr: Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol; 2006 Feb;290(2):G335-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bile salts increase proliferation in a Barrett's-associated adenocarcinoma cell line (SEG-1 cells) by activating ERK and p38 MAPK pathways.
  • [MeSH-minor] Adenocarcinoma / metabolism. Annexin A5 / metabolism. Antimetabolites. Apoptosis / drug effects. Blotting, Western. Bromodeoxyuridine. Cell Count. Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. Esophageal Neoplasms / metabolism. Esophagus / cytology. Esophagus / drug effects. Esophagus / metabolism. Humans. In Situ Nick-End Labeling. Phosphorylation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16239404.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-63621
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antimetabolites; 0 / Bile Acids and Salts; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


42. Lee SH, Park JK, Woo SM, Yoo JW, Ryu JK, Kim YT, Yoon YB: [Natural history of branch-duct type intraductal papillary mucinous neoplasms of the pancreas]. Korean J Gastroenterol; 2007 Jan;49(1):24-30
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten patients underwent surgical resection and pathologic examination revealed one carcinoma in situ and one invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2007 Jan;49(1):50-2 [18167435.001]
  • (PMID = 18167430.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


43. Marrache F, Pendyala S, Bhagat G, Betz KS, Song Z, Wang TC: Role of bone marrow-derived cells in experimental chronic pancreatitis. Gut; 2008 Aug;57(8):1113-20
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chronic pancreatitis is a known risk factor for pancreatic adenocarcinoma.
  • [MeSH-minor] Animals. Bone Marrow Transplantation. Ceruletide. Disease Models, Animal. Immunoenzyme Techniques. In Situ Hybridization. Male. Mice. Mice, Inbred C57BL. Microscopy, Confocal. Y Chromosome

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367560.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; 888Y08971B / Ceruletide
  •  go-up   go-down


44. Rupertus K, Dahlem C, Menger MD, Schilling MK, Kollmar O: Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation. Ann Surg Oncol; 2009 Sep;16(9):2629-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Liver regeneration after hepatectomy stimulates metastatic tumor growth through the release of potent growth factors.
  • However, it is unknown whether RAPA is capable of exerting these effects under the conditions of hepatectomy-associated liver regeneration.
  • CONCLUSIONS: RAPA is capable of inhibiting angiogenesis, microvascular blood perfusion, and tumor growth of colorectal metastasis during hepatectomy-associated liver regeneration.
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Angiogenesis Inhibitors / pharmacology. Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cyclosporine / pharmacology. Female. Humans. Immunoenzyme Techniques. In Situ Nick-End Labeling. Liver Regeneration. Mice. Mice, Inbred BALB C. Mice, Nude. Microcirculation. Protein Kinases / metabolism. TOR Serine-Threonine Kinases. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551445.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


45. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM: Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J; 2010 Jun;12(2):171-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo studies in a resistant subcutaneous SKOV3 human ovarian and in an orthotopic MCF7 human breast adenocarcinoma xenograft showed that the PTX and CER nanoparticle combination therapy reduced the final tumor volume at least twofold over treatment with the standard PTX therapy alone.
  • Additionally, acute evaluation of safety with the combination therapy did not show significant changes in body weight, white blood cell counts, or liver enzyme levels.

  • COS Scholar Universe. author profiles.
  • NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2001 Mar;15(3):719-30 [11259390.001]
  • [Cites] Cancer Treat Rev. 2008 Nov;34(7):592-602 [18538481.001]
  • [Cites] J Clin Invest. 2002 Jul;110(1):3-8 [12093880.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):415-23 [12538495.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2002 May;2(3):387-401 [12678739.001]
  • [Cites] J Exp Ther Oncol. 2003 Jan-Feb;3(1):5-13 [12724854.001]
  • [Cites] J Med Chem. 2003 Nov 6;46(23):4805-17 [14584929.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9534-9 [15210954.001]
  • [Cites] Acta Oncol. 1992;31(2):115-23 [1622625.001]
  • [Cites] Acta Oncol. 1992;31(2):205-13 [1352455.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19530-6 [8702646.001]
  • [Cites] Anticancer Res. 1998 Jan-Feb;18(1B):475-80 [9568165.001]
  • [Cites] Pharm Res. 2005 Dec;22(12):2107-14 [16254763.001]
  • [Cites] Nat Rev Drug Discov. 2006 Mar;5(3):219-34 [16518375.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):477-84 [16862429.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4843-50 [17510414.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1830-8 [17557285.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3193-203 [18483388.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):157-65 [11668492.001]
  • (PMID = 20143195.001).
  • [ISSN] 1550-7416
  • [Journal-full-title] The AAPS journal
  • [ISO-abbreviation] AAPS J
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA119617; United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Ceramides; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Polymers; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2844507
  •  go-up   go-down


46. Yaman B, Nart D, Yilmaz F, Coker A, Zeytunlu M, Kilic M: Biliary intraductal papillary mucinous neoplasia: three case reports. Virchows Arch; 2009 May;454(5):589-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • b-IPMN is classified as adenoma, borderline tumor, carcinoma in situ, and carcinoma, from benign to malignant.
  • Case 2 was diagnosed as carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Papillary / pathology. Cholangiocarcinoma / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Disease-Free Survival. Hepatitis B / complications. Hepatitis B / surgery. Humans. Immunoenzyme Techniques. Liver Cirrhosis / surgery. Liver Cirrhosis / virology. Liver Transplantation. Male. Middle Aged. Mucin 5AC / metabolism. Mucin-1 / metabolism. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2007 Aug;39(4):413-8 [17676483.001]
  • [Cites] Histol Histopathol. 2008 Jan;23 (1):41-50 [17952856.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):902-10 [14562286.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):327-38 [15104295.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):63-9 [9445112.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] Pancreas. 2007 Nov;35(4):348-52 [18090241.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):249-50 [16360969.001]
  • [Cites] Lab Invest. 2004 May;84(5):629-38 [15048136.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1562-6 [2538218.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):34-8 [17240305.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1570-2 [17922173.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] Endoscopy. 2000 May;32(5):389-93 [10817178.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):45-54 [10227724.001]
  • [Cites] J Surg Oncol. 1998 Nov;69(3):162-7 [9846503.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):783-93 [14770435.001]
  • (PMID = 19347361.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1
  •  go-up   go-down


47. Arnold D, Schmoll HJ, Lang H, Knoefel WT, Ridwelski K, Trarbach T, Staib L, Kirchner T, Geissler M, Seufferlein T, Amthauer H, Riess H, Schlitt HJ, Piso P: [Specific treatment situations in metastatic colorectal cancer]. Onkologie; 2010;33 Suppl 4:8-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As far as the management of primary resectable liver metastases is concerned, three approaches are currently competing with each other: surgery alone, surgery with pre- and postoperative chemotherapy, and surgery with postoperative chemotherapy alone.
  • In patients with unresectable liver metastases--with the associated difficulty of classification due to the lack of clear and definitive criteria--preoperative systemic therapy to induce 'conversion' is indicated, in order to allow secondary resection.
  • For synchronous metastasization, the appropriate management depends on the size and extent of liver metastases and of the primary tumor.
  • Small, peripherally lying and safely resectable liver metastases can be removed before or at the same time as the primary tumor, especially if a hemicolectomy is being carried out.
  • If the metastases are unresectable and there is no bleeding or stenosis, the primary tumor can also be left in situ and systemic chemotherapy can be carried out first.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Appendiceal Neoplasms / drug therapy. Appendiceal Neoplasms / mortality. Appendiceal Neoplasms / surgery. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Humans. Neoadjuvant Therapy. Prognosis


48. Stănciulea O, Preda C, Herlea V, Popa M, Ulmeanu D, Vasilescu C: [Rare indication of cephalic duodenopancreatectomy with total gastrectomy--periampullary carcinoma in moderate form of familial adenomatous polyposis]. Chirurgia (Bucur); 2007 Mar-Apr;102(2):215-20
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathological exam revealed duodenal G2 adenocarcinoma pT3N0, and gastric hyperplastic polyps with no signs of dysplasia.
  • The patient underwent transverse colectomy (the histopathological exam--in situ carcinoma).
  • In 2005 was noted a pulmonary nodule, located in the postero-apical segment of upper left lobe, for which left superior lobe resection was performed (the histopathological exam: metastatic adenocarcinoma).
  • Intraoperatively were noted: peritoneal carcinomatosis and multiple liver metastasis.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615925.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


49. Ashurst HL, Varro A, Dimaline R: Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo. Exp Physiol; 2008 Feb;93(2):223-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified endogenous CCK2R expression in several cell lines and used luciferase promoter-reporter constructs to define the minimal promoter required for transcription in human gastric adenocarcinoma, AGS, and rat gastric mucosa, RGM1, cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G787-93 [12181195.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G359-66 [11804858.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]
  • [Cites] Pancreatology. 2003;3(1):47-54 [12649564.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):510-21 [12891554.001]
  • [Cites] Am J Physiol. 1979 Sep;237(3):E284-94 [224710.001]
  • [Cites] Am J Physiol. 1980 Feb;238(2):G135-40 [6244744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Nov;77(11):6917-21 [6256771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3605-9 [1373504.001]
  • [Cites] Science. 1992 Dec 4;258(5088):1662-5 [1333642.001]
  • [Cites] Gastroenterology. 1993 Aug;105(2):449-61 [7687574.001]
  • [Cites] Ann N Y Acad Sci. 1994 Mar 23;713:283-97 [8185170.001]
  • [Cites] Science. 1994 Jul 15;265(5170):410-2 [8023165.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1019-30 [7926455.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2683-9 [8839863.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11825-30 [8876222.001]
  • [Cites] J Clin Invest. 1996 Oct 15;98(8):1918-29 [8878444.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):G161-71 [9038890.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1197-205 [9098003.001]
  • [Cites] Biochim Biophys Acta. 1997 Jul 25;1327(2):213-21 [9271263.001]
  • [Cites] J Biol Chem. 1997 Oct 24;272(43):27015-24 [9341140.001]
  • [Cites] Am J Physiol. 1998 Mar;274(3 Pt 1):G561-8 [9530158.001]
  • [Cites] Mol Psychiatry. 1999 May;4(3):284-5 [10395221.001]
  • [Cites] Am J Physiol. 1999 Jul;277(1 Pt 1):C1-9 [10409103.001]
  • [Cites] Pflugers Arch. 2005 Jan;449(4):344-55 [15480747.001]
  • [Cites] Rocz Akad Med Bialymst. 2005;50:21-36 [16358936.001]
  • [Cites] Gut. 2006 Feb;55(2):295-6 [16407391.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1169-80 [16618411.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1754-63 [16697739.001]
  • [Cites] Physiol Rev. 2006 Jul;86(3):805-47 [16816139.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4421-8 [16547500.001]
  • [Cites] Lab Invest. 2006 Oct;86(10):1037-51 [16894354.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1133-40 [17218472.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):1807-16 [17525249.001]
  • [Cites] Exp Physiol. 2007 Jul;92(4):591-601 [17412751.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):1015-25 [9287997.001]
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):745-81 [10581329.001]
  • [Cites] Cell Tissue Res. 2000 Feb;299(2):289-98 [10741470.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 16;272(3):837-42 [10860839.001]
  • [Cites] J Clin Invest. 2000 Oct;106(8):1021-9 [11032862.001]
  • [Cites] Gut. 2000 Dec;47(6):762-70 [11076873.001]
  • [Cites] Mol Psychiatry. 2001 Jan;6(1):59-65 [11244486.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7661-71 [11113118.001]
  • [Cites] Regul Pept. 2001 Sep 15;101(1-3):25-33 [11495676.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):98-104 [11689954.001]
  • [Cites] Am J Med Genet. 2001 Dec 8;105(8):779-82 [11803530.001]
  • [Cites] Mol Endocrinol. 2002 Dec;16(12):2802-18 [12456801.001]
  • (PMID = 17933865.001).
  • [ISSN] 0958-0670
  • [Journal-full-title] Experimental physiology
  • [ISO-abbreviation] Exp. Physiol.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 072501/Z/03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / Gastrins; 0 / Receptor, Cholecystokinin B; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC2253704
  •  go-up   go-down


50. Grundmann RT, Hölscher AH, Bembenek A, Bollschweiler E, Drognitz O, Feuerbach S, Gastinger I, Hermanek P, Hopt UT, Hünerbein M, Illerhaus G, Junginger T, Kraus M, Meining A, Merkel S, Meyer HJ, Mönig SP, Piso P, Roder J, Rödel C, Tannapfel A, Wittekind C, Woeste G: [Diagnosis of and therapy for gastric cancer--work-flow]. Zentralbl Chir; 2009 Aug;134(4):362-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of and therapy for gastric cancer--work-flow].
  • AIM: This review comments on the diagnosis and treatment of gastric cancer in the classical meaning--excluding adenocarcinoma of the -oesophagogastric junction.
  • Algorithms of diagnosis and care with respect to tumour stage are presented.
  • PREOPERATIVE DIAGNOSIS: Besides oesophagogastroduodenoscopy, endoscopic ultrasonography is necessary for the accurate diagnosis of T categories and as a selection criterion for neoadjuvant chemotherapy.
  • Computed tomography is recommended for preoperative evaluation of tumours > T1, laparoscopy has become an effective stag-ing tool in T3 and T4 tumours avoiding unnecessary laparotomies and improving the detection of small -liver and peritoneal metastases.
  • Hepatic resection for metachronous or synchronous liver metastases is rarely advised since 50 % of patients with liver metastases show concomitant peritoneal dissemination of the disease.
  • [MeSH-major] Gastrectomy. Lymph Node Excision. Stomach Neoplasms / diagnosis. Stomach Neoplasms / surgery
  • [MeSH-minor] Biopsy. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Disease-Free Survival. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Gastroscopy. Humans. Laparoscopy. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging. Palliative Care. Perioperative Care. Peritoneal Lavage. Prognosis. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart.New York.
  • (PMID = 19688686.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 109
  •  go-up   go-down


51. Mao JD, Wu P, Yang YL, Wu J, Huang H: Relationship between expression of gastrin, somatostatin, Fas/FasL and caspases in large intestinal carcinoma. World J Gastroenterol; 2008 May 14;14(18):2802-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell apoptosis was detected by molecular biology in situ apoptosis detecting methods (TUNEL).
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adult. Aged. Apoptosis. Caspase 3 / metabolism. Caspase 8 / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. RNA, Messenger / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Life Sci. 2004 May;61(9):1042-68 [15112052.001]
  • [Cites] Zhonghua Er Ke Za Zhi. 2006 Oct;44(10):774-7 [17229384.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10):1716-20 [15471839.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1268-75 [3315956.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):721-5 [15655830.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Apr;3(2):125-31 [15853632.001]
  • [Cites] Semin Cancer Biol. 2005 Dec;15(6):484-93 [16055342.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42 [16365013.001]
  • [Cites] Horm Metab Res. 2005 Dec;37(12):722-8 [16372224.001]
  • [Cites] Gynecol Endocrinol. 2005 Nov;21(5):248-56 [16373243.001]
  • [Cites] World J Gastroenterol. 2005 Dec 7;11(45):7211-7 [16437675.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):140-9 [16442704.001]
  • [Cites] Regul Pept. 2006 Mar 15;134(1):1-8 [16169610.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1128-33 [17342386.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):91-102 [17395978.001]
  • [Cites] Biomed Pharmacother. 2007 Feb-Apr;61(2-3):137-41 [17258885.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):743-51 [17455148.001]
  • [Cites] Expert Opin Pharmacother. 2007 May;8(7):895-900 [17472535.001]
  • [Cites] Cancer Lett. 2007 Jul 8;252(1):19-35 [17188424.001]
  • [Cites] World J Gastroenterol. 2007 Aug 7;13(29):4015-8 [17663521.001]
  • [Cites] Neuropeptides. 2007 Oct;41(5):293-9 [17688943.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2007 Jun 26;87(24):1704-8 [17825155.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6509-17 [17975164.001]
  • [Cites] Clin Transl Oncol. 2007 Oct;9(10):663-70 [17974527.001]
  • [Cites] Tidsskr Nor Laegeforen. 2007 Nov 1;127(21):2818-23 [17987073.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):851-65, vi [17996794.001]
  • [Cites] Neuro Endocrinol Lett. 2007 Jun;28(3):250-1 [17627256.001]
  • [Cites] World J Gastroenterol. 2006 Apr 7;12(13):2011-5 [16610049.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):5-9 [16625838.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):955-62 [16954443.001]
  • [Cites] Lab Invest. 2006 Oct;86(10):1037-51 [16894354.001]
  • [Cites] Gynakol Geburtshilfliche Rundsch. 2006;46(4):165 [17068400.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3477-83 [17094470.001]
  • [Cites] Curr Med Chem. 2006;13(27):3307-17 [17168853.001]
  • [Cites] Mol Endocrinol. 2007 Jan;21(1):229-46 [17021051.001]
  • [Cites] Nature. 2001 May 17;411(6835):390-5 [11357148.001]
  • [Cites] Regul Pept. 2001 Sep 15;101(1-3):43-9 [11495678.001]
  • [Cites] Pharmacol Ther. 2001 Oct;92(1):57-70 [11750036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):155-60 [12490654.001]
  • [Cites] Kaku Igaku. 2003 May;40(2):185-203 [12884785.001]
  • [Cites] Nihon Rinsho. 2003 Sep;61 Suppl 7:25-30 [14574850.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Dec;285(6):G1097-110 [12881229.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1361-6 [14624161.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1311-23 [15022301.001]
  • [Cites] Rev Prat. 2004 Jan 31;54(2):143-50 [15086056.001]
  • [Cites] Histopathology. 2007 Jan;50(1):30-41 [17204019.001]
  • [Cites] Eur J Histochem. 2006 Oct-Dec;50(4):293-300 [17213038.001]
  • [Cites] Exp Eye Res. 2004 Oct;79(4):465-76 [15381031.001]
  • (PMID = 18473402.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Gastrins; 0 / RNA, Messenger; 51110-01-1 / Somatostatin; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2710719
  •  go-up   go-down


52. Ludwick C, Gilks CB, Miller D, Yaziji H, Clement PB: Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. Int J Gynecol Pathol; 2005 Jul;24(3):205-17
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On follow-up, each patient experienced recurrent disease 7 months to 4.5 years after diagnosis, including hematogenous spread to lung and/or bone and liver in three patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Fatal Outcome. Female. Histocytochemistry. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968194.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


53. Ahn BJ, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS: Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration. Eur J Clin Pharmacol; 2010 Dec;66(12):1235-45
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: It is well known that CPT-11 (irinotecan) is biotransformed to its active metabolite, SN-38, by carboxylesterase in the liver and other tissues.
  • METHODS: Pharmacokinetic data obtained from 16 gastric adenocarcinoma patients with peritoneal seeding were used.
  • CONCLUSIONS: Our results demonstrate that a small fraction of intraperitoneally administered CPT-11 was metabolized in situ to active SN-38 and that the Vss of plasma CPT-11 following IP administration in our patient cohort was lower than that estimated in previous reports following the intravenous administration of CPT-11.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Camptothecin / analogs & derivatives. Neoplasm Seeding. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):175-84 [10676997.001]
  • [Cites] Jpn J Cancer Res. 1995 Jan;86(1):111-6 [7737902.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2182-94 [11489791.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4187-91 [10628373.001]
  • [Cites] Clin Chem. 2003 Nov;49(11):1900-8 [14578322.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3293-301 [12149304.001]
  • [Cites] Ther Drug Monit. 2005 Aug;27(4):536-8 [16044114.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2747-54 [9829738.001]
  • [Cites] Ann Oncol. 1995 Feb;6(2):141-51 [7786822.001]
  • [Cites] Cancer Chemother Pharmacol. 2011 Jan;67(1):5-11 [20213078.001]
  • [Cites] Drug Metab Dispos. 2000 Apr;28(4):423-33 [10725311.001]
  • [Cites] J Med Chem. 1994 Jan 7;37(1):40-6 [8289200.001]
  • [Cites] Clin Pharmacokinet. 1997 Oct;33(4):245-59 [9342501.001]
  • [Cites] Ann Oncol. 1995 Feb;6(2):133-40 [7786821.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 25;795(1):25-34 [12957166.001]
  • [Cites] AAPS J. 2011 Jun;13(2):143-51 [21302010.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):165-70 [9654118.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Nov;29(12 ):2188-90 [12484033.001]
  • [Cites] Clin Pharmacol Ther. 2002 Dec;72 (6):638-47 [12496745.001]
  • [Cites] Biomed Chromatogr. 2003 Dec;17 (8):493-9 [14648604.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Oct;28(11):1505-7 [11707965.001]
  • (PMID = 20827550.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


54. Coman I, Crişan N, Petrut B, Bungărdean C, Cristea T, Crişan D: Hepatic and skin metastases after laparoscopic radical prostatectomy for prostate cancer. J Gastrointestin Liver Dis; 2007 Sep;16(3):333-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma. Carcinoma in Situ. Liver Neoplasms / secondary. Prostatic Neoplasms. Skin Neoplasms / secondary
  • [MeSH-minor] Follow-Up Studies. Humans. Laparoscopy. Liver / pathology. Male. Middle Aged. Neoplasm Staging. Prostate / pathology. Surgical Instruments. Time Factors. Transurethral Resection of Prostate

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925932.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


55. Song Y, Huang J, Wang JW: [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma]. Chin J Cancer; 2010 Jan;29(1):76-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HER2/neu status in 83 advanced gastric carcinomas was evaluated using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma. Genes, erbB-2. Receptor, ErbB-2 / metabolism. Stomach Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / secondary. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038314.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


56. Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Wong RS, Cheng GY, Tang WK, Cheng CH, Tang JC, Chan AS: Mechanistic insight into a novel synthetic cantharidin analogue in a leukaemia model. Int J Mol Med; 2006 Aug;18(2):375-9
Hazardous Substances Data Bank. CANTHARIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, we demonstrated that the novel synthetic cantharidin analogue CAN 032 possessed apoptotic activity on two human hepatoma cell lines Hep3B hepatocellular carcinoma and SK-Hep-1 liver adenocarcinoma.
  • [MeSH-minor] Adult. Animals. Bone Marrow Cells / cytology. Bone Marrow Cells / metabolism. Cell Cycle. Cells, Cultured. Enzyme Inhibitors / chemical synthesis. Enzyme Inhibitors / pharmacology. Female. Humans. In Situ Nick-End Labeling. Insects. Male. Mitochondria / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820948.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CAN 032; 0 / Enzyme Inhibitors; 0 / Thiazoles; IGL471WQ8P / Cantharidin
  •  go-up   go-down


57. Caputi Iambrenghi O, Ugenti I, Martines G, Marino F, Francesco Altomare D, Memeo V: Endoscopic management of large colorectal polyps. Int J Colorectal Dis; 2009 Jul;24(7):749-53
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At histology, most of polyps (131) were adenomas (nine with adenocarcinoma in situ).

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):256-7 [8857147.001]
  • [Cites] Gastrointest Endosc. 1997 Oct;46(4):387-9 [9351059.001]
  • [Cites] Dis Colon Rectum. 1984 Nov;27(11):726-9 [6499606.001]
  • [Cites] Am J Gastroenterol. 1987 Jul;82(7):615-8 [3605021.001]
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):189-95 [8857132.001]
  • [Cites] Gastrointest Endosc. 1998 Jun;47(6):496-9 [9647375.001]
  • [Cites] Am Fam Physician. 1975 Sep;12 (3):125-32 [1163409.001]
  • [Cites] Am J Clin Pathol. 1974 Oct;62(4):447-54 [4416491.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1967-79 [10784639.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):371-5 [11868011.001]
  • [Cites] Dis Colon Rectum. 2001 Jan;44(1):112-8 [11805571.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1036-46 [11036279.001]
  • [Cites] Endoscopy. 2005 Nov;37(11):1116-22 [16281142.001]
  • [Cites] Gastrointest Endosc. 1989 Nov-Dec;35(6):536-40 [2689263.001]
  • [Cites] Gastrointest Endosc. 1999 Jan;49(1):113-5 [9869736.001]
  • [Cites] Gastrointest Endosc. 1998 Nov;48(5):477-84 [9831835.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1020-4 [12153628.001]
  • [Cites] Am J Surg. 1977 Dec;134(6):770-1 [596545.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):1-7 [15672048.001]
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):183-8 [8857131.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1513-6 [14605571.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1081-90 [11036286.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Int Abstr Surg. 1958 Jun;106(6):519-38 [13556509.001]
  • [Cites] ANZ J Surg. 2003 Dec;73(12):988-95 [14632888.001]
  • [Cites] Gastrointest Endosc. 1999 Jun;49(6):731-5 [10343218.001]
  • [Cites] J Clin Gastroenterol. 1992 Dec;15(4):347-51 [1294644.001]
  • (PMID = 19259689.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Shi G, Zhu L, Sun Y, Bettencourt R, Damsz B, Hruban RH, Konieczny SF: Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. Gastroenterology; 2009 Apr;136(4):1368-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Invasive pancreatic ductal adenocarcinoma is thought to originate from duct-like lesions called pancreatic intraepithelial neoplasia (PanIN).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anat Rec. 2000 Jun 1;259(2):157-67 [10820318.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):286-93 [11159909.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):519-30 [11696558.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Gut. 2002 Dec;51(6):849-52 [12427788.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] J Cell Sci. 2003 Aug 15;116(Pt 16):3315-25 [12829745.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Mech Dev. 2004 Mar;121(3):261-72 [15003629.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2673-81 [15024058.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1121-35 [1693546.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Aug 28;237(3):752-7 [9299439.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):81-91 [15731576.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12668-75 [15665001.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1606-25 [15887154.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):211-26 [16549325.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1123-32 [17170023.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):266-79 [17785207.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8121-30 [17804724.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Annu Rev Pathol. 2008;3:157-88 [18039136.001]
  • [Cites] Gastroenterology. 2008 Nov;135(5):1687-97 [18762186.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18907-12 [19028876.001]
  • (PMID = 19249398.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK055489-10; United States / NCI NIH HHS / CA / P50CA62924; United States / NCI NIH HHS / CA / R01 CA124586-02; United States / NCI NIH HHS / CA / P50 CA062924; United States / NIDDK NIH HHS / DK / DK055489-10; United States / NCI NIH HHS / CA / CA124586-02; United States / NIDDK NIH HHS / DK / DK55489; United States / NIDDK NIH HHS / DK / R01 DK055489; United States / NCI NIH HHS / CA / R01 CA124586; United States / NCI NIH HHS / CA / CA124586
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Mist1 protein, mouse; 0 / Receptors, Notch; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ NIHMS182460; NLM/ PMC2845927
  •  go-up   go-down


59. Zen Y, Inoue D, Kitao A, Onodera M, Abo H, Miyayama S, Gabata T, Matsui O, Nakanuma Y: IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases. Am J Surg Pathol; 2009 Dec;33(12):1886-93
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, 1 patient was found to have a primary adenocarcinoma against a background of IgG4-related lung disease during follow up.
  • [MeSH-minor] Adult. Aged. Biomarkers / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Steroids / therapeutic use. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898222.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin G; 0 / Steroids
  •  go-up   go-down


60. Haveri H, Westerholm-Ormio M, Lindfors K, Mäki M, Savilahti E, Andersson LC, Heikinheimo M: Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterol; 2008;8:9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Samples of normal and neoplastic gastrointestinal tract from children and adults were subjected to RNA in situ hybridization with 33P labelled probes and immunohistochemistry, using an avidin-biotin immunoperoxidase system.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colonic Neoplasms / genetics. GATA4 Transcription Factor / metabolism. GATA6 Transcription Factor / metabolism. Gastric Mucosa / metabolism. Rectal Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1061-72 [9136933.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1696-710 [16285967.001]
  • [Cites] Cancer Biol Ther. 2005 Oct;4(10):1050-4 [16258256.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G297-306 [16603485.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):14-29 [16831586.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):9060-70 [16940177.001]
  • [Cites] Dev Biol. 2002 Jan 1;241(1):34-46 [11784093.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1178-83 [11861401.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):279-89 [11864602.001]
  • [Cites] Genes Dev. 2002 Apr 1;16(7):784-9 [11937486.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 7;1576(1-2):198-202 [12031502.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3136-43 [12130579.001]
  • [Cites] Biochim Biophys Acta. 2000 Feb 29;1490(3):324-32 [10684977.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):184-8 [10942535.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3476-83 [10999851.001]
  • [Cites] Circ Res. 2000 Oct 13;87(8):699-704 [11029406.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G58-67 [11123198.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1321-57 [11578958.001]
  • [Cites] FEBS Lett. 1997 May 19;408(2):121-3 [9187350.001]
  • [Cites] Am J Physiol. 1998 Feb;274(2 Pt 1):G314-24 [9486185.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2901-11 [9566909.001]
  • [Cites] Development. 1998 Dec;125(24):4909-17 [9811575.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3579-90 [9832509.001]
  • [Cites] Front Biosci. 1999 Mar 15;4:D286-98 [10077541.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(2):71-6 [10190312.001]
  • [Cites] Circ Res. 1999 Apr 2;84(6):647-54 [10189352.001]
  • [Cites] Mol Med. 1999 Jul;5(7):490-501 [10449810.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):952-60 [15541382.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7917-24 [15585625.001]
  • [Cites] J Cell Physiol. 2005 Apr;203(1):15-26 [15389642.001]
  • [Cites] J Mol Histol. 2005 Feb;36(1-2):15-24 [15703995.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):660-8 [12152167.001]
  • [Cites] J Pathol. 2002 Aug;197(5):582-8 [12210076.001]
  • [Cites] Mol Pharmacol. 2003 Feb;63(2):368-77 [12527808.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4705-12 [12468531.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8429-39 [14612389.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):668-76 [15146555.001]
  • [Cites] Pathol Int. 2004 Jun;54(6):408-12 [15144399.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G899-909 [15178553.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1086-99 [14715527.001]
  • [Cites] Blood. 1992 Aug 1;80(3):575-81 [1638017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10876-80 [8248184.001]
  • [Cites] Dev Biol. 1994 Aug;164(2):361-73 [8045339.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):309-22 [8660897.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1559-67 [9136834.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1048-60 [9136932.001]
  • [Cites] Gut. 2005 Sep;54(9):1321-31 [16099799.001]
  • (PMID = 18405344.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA4 Transcription Factor; 0 / GATA6 Transcription Factor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2323380
  •  go-up   go-down


61. Milne AN, Carneiro F, O'Morain C, Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet; 2009 Nov;126(5):615-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Cadherins / genetics. Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Environment. Helicobacter Infections / complications. Helicobacter pylori. Humans. Interleukin-1beta / genetics. Precancerous Conditions / epidemiology. Precancerous Conditions / etiology. Precancerous Conditions / genetics. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Science. 1999 Apr 23;284(5414):651-4 [10213689.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1319-29 [10348815.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 [10433620.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2373-9 [10483994.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8492-5 [15574751.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2354-66 [15735748.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1618-23 [17582605.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):659-72 [17681184.001]
  • [Cites] Am J Gastroenterol. 2007 Sep;102(9):1878-92 [17640324.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):926-36 [17854597.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2013-8 [17690113.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Gut. 2007 Nov;56(11):1503-11 [17337464.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Cancer Biol Ther. 2007 Jun;6(6):832-9 [17568183.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4887-94 [17971584.001]
  • [Cites] J Pathol. 2008 Nov;216(3):295-306 [18788075.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2397-403 [18755583.001]
  • [Cites] Cancer Cell. 2008 Nov 4;14(5):408-19 [18977329.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1704-11 [18941457.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):465-77 [16237216.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10912-20 [16322238.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):643-9 [16247479.001]
  • [Cites] Int J Surg Pathol. 2006 Jan;14(1):21-33 [16501831.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):564-72 [16474375.001]
  • [Cites] Mod Pathol. 2006 May;19(5):675-83 [16528374.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1975-84 [16762620.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):246-58 [16831607.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):406-15 [16832408.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1558-66 [16646055.001]
  • [Cites] Gut. 2006 Nov;55(11):1538-44 [16785284.001]
  • [Cites] Gut. 2006 Nov;55(11):1532-3 [17047103.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Carcinogenesis. 2006 Nov;27(11):2250-7 [16774936.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1643-51 [17071588.001]
  • [Cites] Eur J Cancer Prev. 2008 Jun;17(3):195-200 [18414189.001]
  • [Cites] Mod Pathol. 2008 May;21(5):544-52 [18246045.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):2909-17 [18483357.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):685-90 [18311113.001]
  • [Cites] J Hum Genet. 2008;53(6):479-89 [18350251.001]
  • [Cites] JAMA. 2008 May 28;299(20):2423-36 [18505952.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):730-40 [18488030.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):799-809 [18391748.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):925-32 [18440592.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2876-82 [18539967.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2655-63 [18442100.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):490-6 [18396115.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4623-30 [18559507.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):91-9 [18474244.001]
  • [Cites] J Med Genet. 1999 Dec;36(12):873-80 [10593993.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):36-47 [10611152.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Apr;27(4):403-11 [10719371.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] BMJ. 2000 Jun 17;320(7250):1642-6 [10856067.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):729-35 [10980112.001]
  • [Cites] J Pathol. 2000 Nov;192(3):301-6 [11054712.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6361-70 [11101509.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):965-8 [11286478.001]
  • [Cites] Cell. 2001 May 4;105(3):369-77 [11348593.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1923-31 [11448905.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1348-53 [11729114.001]
  • [Cites] J Biol Chem. 2001 Dec 28;276(52):48693-701 [11668179.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):159-64 [9892201.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1090-5 [10070967.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):1267; author reply 1268 [18395110.001]
  • [Cites] Future Oncol. 2008 Apr;4(2):229-39 [18407736.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):774-80 [18342503.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1443-51 [18319718.001]
  • [Cites] Semin Diagn Pathol. 2008 Nov;25(4):274-87 [19013893.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):58-64 [18755497.001]
  • [Cites] Oncogene. 2008 Nov 24;27(55):7047-54 [19029944.001]
  • [Cites] Int J Epidemiol. 2008 Dec;37(6):1316-25 [18641418.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2385-93 [18775915.001]
  • [Cites] Am J Epidemiol. 2008 Dec 15;168(12):1409-15 [18945691.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):434-9 [18821580.001]
  • [Cites] Gut. 2009 Jan;58(1):16-23 [18838486.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):291-8 [19118057.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S161-6 [19120891.001]
  • [Cites] Oncogene. 2008 Jul 10;27(30):4255-60 [18427545.001]
  • [Cites] Lancet. 2008 Aug 2;372(9636):392-7 [18675689.001]
  • [Cites] Future Oncol. 2008 Aug;4(4):553-9 [18684065.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1175-81 [18637055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1997-2001 [18708389.001]
  • [Cites] Hum Pathol. 2008 Sep;39(9):1360-9 [18614201.001]
  • [Cites] J Clin Gastroenterol. 2008 Sep;42(8):910-5 [18645534.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] Cancer. 2008 Sep 1;113(5 Suppl):1225-33 [18720378.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7025-34 [18757416.001]
  • [Cites] Lancet Oncol. 2008 Sep;9(9):827 [18770893.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2402-8 [18768510.001]
  • [Cites] Helicobacter. 2008 Oct;13 Suppl 1:28-34 [18783519.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):249-55 [18688641.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):593-6 [2847662.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6605-9 [2573419.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1552-5 [11813570.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):689-96 [11875002.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):331-41 [12044009.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 7;294(2):470-9 [12051735.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):341-50 [12163453.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G767-77 [12181193.001]
  • [Cites] Nat Med. 2002 Sep;8(9):1011-7 [12195435.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Nov;35(3):219-31 [12353264.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1406; author reply 1406-7 [12360507.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):888-91 [12373604.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1680-7 [12441323.001]
  • [Cites] Histopathology. 2003 Feb;42(2):128-36 [12558744.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3664-70 [12446738.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1408-19 [12730880.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):364-71 [12891537.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6643-50 [14583457.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):606-12 [14696128.001]
  • [Cites] Gut. 2004 Feb;53(2):195-200 [14724149.001]
  • [Cites] J Pathol. 2004 Jun;203(2):681-7 [15141383.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1976-83 [15188375.001]
  • [Cites] Gene. 2004 Oct 27;341:1-17 [15474284.001]
  • [Cites] Oncogene. 1988 Mar;2(3):283-7 [3281095.001]
  • [Cites] Int J Cancer. 1996 Feb 20;69(1):38-43 [8600057.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):382-7 [8775994.001]
  • [Cites] Cancer Lett. 1997 Jan 30;112(2):161-6 [9066723.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):402-5 [9537325.001]
  • [Cites] Gut. 1998 Feb;42(2):300-3 [9536959.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):410-2 [9708215.001]
  • [Cites] Eur Surg Res. 1989;21(6):313-8 [2633929.001]
  • [Cites] BMJ. 1991 Jun 1;302(6788):1302-5 [2059685.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Gut. 1992 Jan;33(1):16-20 [1740271.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5853-5 [8261393.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1645-8 [8137274.001]
  • [Cites] Gut. 1993 Aug;34(8):1038-41 [8174949.001]
  • [Cites] Scand J Gastroenterol. 1994 May;29(5):425-9 [8036458.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:177-240 [7715070.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Tumour Biol. 2008;29(6):343-50 [19023234.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):160-5 [18669867.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):236-46 [18996125.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):71-7 [19015200.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):551-7 [19156150.001]
  • [Cites] Eur J Cancer. 2009 Feb;45(3):461-9 [19081245.001]
  • [Cites] Scand J Gastroenterol. 2009;44(3):339-45 [19031173.001]
  • [Cites] Cancer Sci. 2009 Mar;100(3):413-8 [19154407.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2050-6 [19223545.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):500-5 [19147860.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2677-82 [19170207.001]
  • [Cites] Hum Mol Genet. 2009 May 1;18(9):1545-55 [19168852.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):2995-3002 [19383819.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 Jun;21(6):630-5 [19295440.001]
  • [Cites] Hum Pathol. 2009 Jun;40(6):769-77 [19269014.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2137-48 [19269290.001]
  • [Cites] Forum Nutr. 2007;60:91-6 [17684404.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2360-72 [17545690.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1855-61 [17505514.001]
  • [Cites] Gut. 2007 Jul;56(7):1023 [17566037.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] J Pathol. 2006 Dec;210(4):398-404 [16981245.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):936-46 [17128210.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2427-34 [17164366.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):60-9 [17200707.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1330-5 [17187359.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):15-28 [17311530.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] Nat Med. 2007 Apr;13(4):470-6 [17401375.001]
  • [Cites] Nat Genet. 2007 May;39(5):605-13 [17450141.001]
  • [Cites] Virchows Arch. 2007 May;450(5):519-27 [17429689.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10181-9 [17974958.001]
  • [Cites] Helicobacter. 2007 Nov;12 Suppl 2:39-44 [17991175.001]
  • [Cites] Gut. 2007 Dec;56(12):1665-70 [17698860.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1989-98 [18054570.001]
  • [Cites] Am J Epidemiol. 2008 Jan 1;167(1):7-14 [17971340.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):25-30 [17513507.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):306-23 [18166359.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):234-43 [18176605.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):244-52 [18176606.001]
  • [Cites] BMC Cancer. 2007;7:206 [17996038.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jan 15;180(2):110-4 [18206535.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):707-14 [18245470.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):500-10 [18242216.001]
  • [Cites] J Gastroenterol. 2008;43(2):115-23 [18306985.001]
  • [Cites] Am J Clin Pathol. 2008 Apr;129(4):613-21 [18343789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4358-63 [18332421.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2286-93 [18224687.001]
  • [Cites] Cancer Sci. 2008 May;99(5):836-42 [18294278.001]
  • (PMID = 19657673.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / Interleukin-1beta
  • [Number-of-references] 179
  • [Other-IDs] NLM/ PMC2771140
  •  go-up   go-down


62. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG: Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol; 2005 Jul;174(1):93-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pure neuroendocrine-type histology was identified in 16 cases, including 1 with small and large cell features, while the remaining 9 had mixed histology, that is transitional cell carcinoma in 8 and adenocarcinoma in 1.
  • A total of 19 patients (76%) had lymph node involvement, of whom 2 had small liver metastases found intraoperatively, while only 4 (16%) had organ confined tumors and 2 (8%) had extravesical, node negative disease.
  • These tumors tended to have a flat, ulcerative gross appearance with lymphovascular invasion, carcinoma in situ and necrosis present microscopically.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947585.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Monte MJ, Ballestero MR, Briz O, Perez MJ, Marin JJ: Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J Pharmacol Exp Ther; 2005 Oct;315(1):24-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proapoptotic effect of cisplatin bile acid derivatives Bamet-R2 [cis-diamminechloro-cholylglycinate-platinum(II)] and Bamet-UD2 [cis-diammine-bisursodeoxycholate-platinum(II)], developed to treat liver and intestinal tumors, was investigated in vitro using human enterohepatic cells HepG2 (hepatoblastoma), LS 174T (colon adenocarcinoma), and its cisplatin-resistant subline LS 174T/R.
  • Oral administration of Bamet-UD2 to mice induced mild apoptosis in the small intestine (ileum > duodenum), which was not severe enough to modify its structure or function as determined by water absorption and glycocholic acid uptake by in situ perfused ileum.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985617.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bamet-UD2; 0 / DNA Adducts; 0 / Organoplatinum Compounds; 0 / diamminebis(ursodeoxycholate(O,O'))platinum(II); 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


64. Davé SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D, Sepulveda AR, Fink MP, Lotze MT, Plevy SE: Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol; 2009 Sep;86(3):633-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis.
  • Signals from stressed cells and the enteric microbiota activate macrophages and dendritic cells and mediate intestinal inflammation.
  • HMGB1 serves as an immunogenic stimuli causing release of inflammatory cytokines by myeloid cells.
  • Ethyl pyruvate inhibits secretion of HMGB1 and improves survival in models of endotoxemia and hemorrhagic shock.
  • We reasoned that ethyl pyruvate may be protective in colitis, which involves similar inflammatory pathways.
  • In IL-10(-/-) mice with established chronic colitis, ethyl pyruvate administration ameliorated colitis and reduced intestinal cytokine production.
  • IL-10(-/-) mice demonstrated increased intestinal HMGB1 expression and decreased expression of RAGE compared with wild-type mice.
  • Fecal HMGB1 levels were decreased in ethyl pyruvate-treated mice.
  • Furthermore, ethyl pyruvate induced HO-1 expression in intestinal tissue.
  • In TNBS-induced colitis, intrarectal administration of ethyl pyruvate resulted in amelioration of colitis and reduced intestinal cytokine production.
  • In LPS-activated murine macrophages, ethyl pyruvate decreased expression of IL-12 p40 and NO production but did not affect IL-10 levels.
  • Ethyl pyruvate did not inhibit nuclear translocation of NF-kappaB family members but attenuated NF-kappaB DNA binding.
  • Additionally, ethyl pyruvate induced HO-1 mRNA and protein expression and HO-1 promoter activation.
  • Moreover, ethyl pyruvate prevented nuclear-to-cytoplasmic translocation of HMGB1.
  • In conclusion, the HMGB1/RAGE pathway has pathophysiologic and diagnostic significance in experimental colitis.
  • Ethyl pyruvate and other strategies to inhibit HMGB1 release and function represent promising interventions in chronic inflammatory diseases.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jul 15;165(2):618-22 [10878331.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27694-702 [10874044.001]
  • [Cites] J Exp Med. 2000 Aug 21;192(4):565-70 [10952726.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18519-28 [11279072.001]
  • [Cites] Crit Care Med. 2001 Aug;29(8):1513-8 [11505117.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):949-55 [11581294.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1768-73 [11734424.001]
  • [Cites] Annu Rev Immunol. 2002;20:495-549 [11861611.001]
  • [Cites] Antioxid Redox Signal. 2002 Apr;4(2):249-57 [12006176.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1987-2000 [12055604.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):191-5 [12110890.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):790-802 [12198705.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12351-6 [12209006.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jan;304(1):464-76 [12490623.001]
  • [Cites] Crit Care Med. 2003 Jan;31(1 Suppl):S51-6 [12544977.001]
  • [Cites] Gut. 2003 Jun;52(6):847-53 [12740341.001]
  • [Cites] Shock. 2003 Dec;20(6):521-8 [14625476.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):104-12 [14691478.001]
  • [Cites] Free Radic Biol Med. 2004 Jan 15;36(2):233-47 [14744635.001]
  • [Cites] J Intern Med. 2004 Mar;255(3):344-50 [14871458.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7370-7 [14660645.001]
  • [Cites] J Biol Chem. 2004 Mar 12;279(11):10776-83 [14679201.001]
  • [Cites] J Lab Clin Med. 1970 Mar;75(3):410-21 [4392030.001]
  • [Cites] Food Addit Contam. 1984 Jul-Sep;1(3):283-8 [6537353.001]
  • [Cites] J Biol Chem. 1994 Feb 18;269(7):4705-8 [7508926.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5258-67 [7565674.001]
  • [Cites] J Clin Invest. 1996 Aug 15;98(4):1010-20 [8770874.001]
  • [Cites] Nat Med. 1996 Sep;2(9):998-1004 [8782457.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4572-88 [9234715.001]
  • [Cites] J Leukoc Biol. 2000 Mar;67(3):405-14 [10733102.001]
  • [Cites] Cell. 1999 Jun 25;97(7):889-901 [10399917.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50019-24 [15381690.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Mar;312(3):1097-105 [15525791.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1135-43 [15795240.001]
  • [Cites] J Immunol. 2005 Oct 15;175(8):5412-22 [16210648.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):221-9 [16354693.001]
  • [Cites] J Exp Med. 2005 Dec 19;202(12):1703-13 [16365149.001]
  • [Cites] Mol Pharmacol. 2006 Mar;69(3):1033-40 [16354769.001]
  • [Cites] Shock. 2006 Aug;26(2):174-9 [16878026.001]
  • [Cites] Immunity. 2006 Aug;25(2):319-29 [16879997.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):84-91 [17035340.001]
  • [Cites] J Intern Med. 2007 Apr;261(4):349-62 [17391109.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Aug 24;360(2):394-400 [17599806.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):427-34 [17653185.001]
  • [Cites] Trends Immunol. 2007 Oct;28(10):429-36 [17845865.001]
  • [Cites] J Cell Biol. 2007 Oct 8;179(1):33-40 [17923528.001]
  • [Cites] Nat Protoc. 2007;2(10):2307-11 [17947970.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):577-94 [18242222.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2531-7 [18250463.001]
  • [Cites] Infect Immun. 2000 Dec;68(12):7010-7 [11083826.001]
  • (PMID = 19454652.001).
  • [ISSN] 1938-3673
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK054452-09; United States / NIEHS NIH HHS / ES / F30 ES013617; United States / NCI NIH HHS / CA / 1 P01 CA 101944; United States / NIDDK NIH HHS / DK / R01 DK054452; United States / NIDDK NIH HHS / DK / P30 DK34987; United States / NIDDK NIH HHS / DK / 2 R01 DK54452
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Annexin A5; 0 / Cytokines; 0 / HMGB1 Protein; 0 / Interleukin-12 Subunit p40; 0 / MAP1LC3 protein, mouse; 0 / Microtubule-Associated Proteins; 0 / Pyruvates; 0 / Receptors, Immunologic; 03O98E01OB / ethyl pyruvate; 130068-27-8 / Interleukin-10; 31C4KY9ESH / Nitric Oxide; EC 2.4.2.30 / Parp1 protein, mouse; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; I223NX31W9 / Fluorescein-5-isothiocyanate
  • [Other-IDs] NLM/ PMC2735284
  •  go-up   go-down






Advertisement